Bispecific Anti-human a-beta / human transferrin receptor antibody and use method thereof

Bispecific antibodies targeting A-beta and the transferrin receptor provide a promising treatment for Alzheimer's by degrading plaques and inhibiting their formation, addressing the limitations of existing therapies.

JP2024160260AActive Publication Date: 2024-11-13F HOFFMANN LA ROCHE & CO AG
View PDF 3 Cites 0 Cited by

Patent Information

Application Number
JP2024122543
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2015-10-02
Filing Date
2024-07-29
Publication Date
2024-11-13
Estimated Expiration
2036-09-30

AI Technical Summary

Technical Problem

Current treatments for Alzheimer's disease, such as cholinesterase inhibitors and NMDA receptor antagonists, provide only mild symptomatic relief and have adverse effects, while immunomodulatory approaches lack efficacy in significantly slowing or halting disease progression.

Method used

Development of bispecific antibodies that bind to both human A-beta protein and the transferrin receptor, utilizing a unique antibody structure with specific mutations and an additional Fab fragment to enhance targeting and efficacy.

Benefits of technology

The bispecific antibodies effectively cross the blood-brain barrier, degrade beta-amyloid plaques, and inhibit plaque formation, offering a potential therapeutic approach to slow or halt Alzheimer's disease progression.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 2024160260000001
    Figure 2024160260000001
  • Figure 2024160260000002
    Figure 2024160260000002
  • Figure 2024160260000003
    Figure 2024160260000003
Patent Text Reader

Abstract

To provide a bispecific antibody for the treatment of Alzheimer's disease, pharmaceutical compositions containing the antibody, and uses thereof.SOLUTION: Provided is a bispecific antibody containing: a) one antibody containing two pairs each of an antibody light chain and an antibody heavy chain, with a binding site formed by each of the pairs of the heavy chain and the light chain specifically binding to a first antigen; and b) one additional Fab fragment, the additional Fab fragment being fused to the C-terminus of one of the heavy chains of the antibody, and the binding site specifically binding to a second antigen, wherein each of the antibody light chains includes a specific mutation in a constant light chain domain (CL), each of the antibody heavy chains including a specific mutation in a first constant heavy chain domain (CH1), the additional Fab fragment specifically binding to the second antigen including a domain crossover such that the CL and the CH1 are replaced by each other, and the first antigen being human A-beta protein and the second antigen being human transferrin receptor.SELECTED DRAWING: None
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] FIELD OF THEINVENTION The present invention relates to bispecific antibodies against human A-beta and the human transferrin receptor, methods for their production, pharmaceutical compositions containing these antibodies, and uses thereof.

[0002] background Approximately 70% of all cases of dementia are due to Alzheimer's disease, which is associated with selective damage to brain regions and neural circuits that are critical for cognition. Alzheimer's disease is characterized by neurofibrillary tangles, especially in pyramidal neurons of the hippocampus, and numerous amyloid plaques, which mainly contain dense cores and hollow circles of amyloid deposits.

[0003] Extracellular neuritic plaques contain large amounts of fibrillar peptides called "amyloid beta", "A-beta", "Aβ4", "β-A4", or "Aβ" (see Selkoe, Ann. Rev. Cell Biol. 10 (1994) 373-403; Koo PNAS 96 (1999) 9989-9990; US 4,666,829; Glenner BBRC 12 (1984) 1131). This amyloid is derived from the "Alzheimer's Precursor Protein / P-Amyloid Precursor Protein" (APP). APP is an integral membrane glycoprotein (see Sisodia PNAS 89 (1992) 6075) that is endoproteolytically cleaved within the AP sequence by the plasma membrane protease α-secretase (see Sisodia (1992), Joe. cit.). Furthermore, further secretase activities, in particular β-secretase activity and γ-secretase activity, lead to the extracellular release of amyloid β (Aβ) containing either 39 amino acids (Aβ39), 40 amino acids (Aβ40), 42 amino acids (Aβ42) or 43 amino acids (Aβ43) (see Sinha PNAS 96 (1999) 11094-1053; Price, Science 282 (1998) 1078-1083; WO 00 / 72880, or Hardy, TINS ​​20 (1997) 154).

[0004] Note that A-beta has several naturally occurring forms, the human forms being referred to as Aβ39, Aβ40, Aβ41, Aβ42, and Aβ43 above. The most prominent form, Aβ42, has the amino acid sequence (starting from the N-terminus): DAEFRHDSGYEVHHQKLVFFAEDVGSNKGAIIGLMVGGVVIA (SEQ ID NO: 05). Aβ41, Aβ40, Aβ39 are missing the C-terminal amino acids A, IA, and VIA, respectively. In the Aβ43 form, an additional threonine residue is included at the C-terminus of the above sequence.

[0005] The time required to nucleate Aβ40 fibrils has been shown to be significantly longer than that required to nucleate Aβ42 fibrils (see, e.g., Lansbury, Jr., PT and Harper, JD, Ann. Rev. Biochem. 66 (1997) 385-407). As reviewed by Wagner (J. Clin. Invest. 104 (1999) 1239-1332), Aβ42 is more frequently found associated with senile plaques and appears to be more fibrillar in vitro. Aβ42 has also been suggested to play a role as a "seed" in the nucleation-dependent polymerization of ordered non-crystalline Aβ peptides (see, e.g., Jarrett, Cell 93 (1993) 1055-1058). Altered APP processing and / or the generation of extracellular plaques containing proteinaceous deposits is known from Alzheimer's pathology as well as from subjects suffering from other neurological and / or neurodegenerative disorders, including Down's syndrome, Hereditary Cerebral Hemorrhage with Amyloidosis of the Dutch Type, Parkinson's Disease, ALS (amyotrophic lateral sclerosis), Creutzfeldt-Jakob Disease, HIV-associated dementia, and motor neuropathy, among others.

[0006] So far, only limited medical intervention plans have been described for amyloid-related diseases. For example, cholinesterase inhibitors such as galantamine, rivastigmine, or donepezil have been considered beneficial in Alzheimer's patients with only mild to moderate disease. However, adverse events due to the cholinergic effects of these drugs have also been reported. Although these cholinergic enhancement treatments provide some symptomatic effects, the therapeutic response is unsatisfactory for the majority of treated patients. It is estimated that significant cognitive improvement occurs in only about 5% of treated patients, and there is little evidence that treatment significantly alters the course of this progressive disease.

[0007] Consequently, there remains a great clinical need for more effective treatments, particularly those that can halt or slow the progression of the disease, and more recently, NMDA receptor antagonists such as memantine have been used.

[0008] However, adverse events due to pharmacological activity have been reported. Moreover, such treatment with these NMDA receptor antagonists can be considered merely a symptomatic approach, rather than a symptom-modifying approach.

[0009] Also, immunomodulatory approaches for the treatment of amyloid-related disorders are presented. WO 99 / 27944 discloses a conjugate that comprises a portion of A-beta peptide and a carrier molecule, which should enhance immune response. Another active immunization approach is described in WO 00 / 72880, where A-beta fragments are also used to induce immune response.

[0010] Also, passive immunization approaches using general anti-A-beta antibodies are presented in WO 99 / 27944 or WO 01 / 62801, and specific humanized antibodies against parts of A-beta are described in WO 02 / 46237, WO 02 / 088306, and WO 02 / 088307. WO 00 / 77178 describes antibodies that bind to the transition state adopted by β-amyloid during hydrolysis. WO 03 / 070760 discloses antibody molecules that recognize two discontinuous amino acid sequences on the A-beta peptide.

[0011] WO2014 / 033074 relates to a blood-brain barrier shuttle that binds to a receptor on the blood-brain barrier and a method for using the same. Blood-brain barrier drug delivery of an IgG fusion protein with a transferrin receptor monoclonal antibody is reported by Pardridge, W. (Exp. Opin. Drug Deliv. 12 (2015) 207-222). Yu, YJ et al. (Sci. Translat. Med. 6 (2014) 261ra154-261ra154) reported that a therapeutic bispecific antibody crosses the blood-brain barrier in non-human primates. Dissociation of amyloid plaques in the brains of Alzheimer's transgenic mice by daily subcutaneous administration of a tetravalent bispecific antibody targeting the transferrin receptor and abeta amyloid peptide was reported by Sumbria, RK, et al. (Mol. Pharm. 10 (2013) 3507-3513). Increased brain penetration and efficacy of therapeutic antibodies using a monovalent molecular shuttle was reported by Niewoehner, J., et al. (Neuron 81 (2014) 49-609).

[0012] overview Herein, we report a bispecific antibody comprising: a) a (full-length) antibody comprising two pairs of (full-length) antibody light chains and (full-length) antibody heavy chains (full-length), the binding site formed by each of the (full-length) heavy chain and (full-length) light chain pairs specifically binding to a first antigen, and b) one additional Fab fragment, in which the binding site of the additional Fab fragment specifically binds to a second antigen, is fused to the C-terminus of one of the heavy chains of the (full-length) antibody; each of the (full length) antibody light chains comprises in the constant light domain (CL) the amino acid residue arginine at position 123 (instead of the wild type glutamic acid residue; E123R mutation) and the amino acid residue lysine at position 124 (instead of the wild type glutamine residue; Q124K mutation) (numbering according to Kabat); each of the (full length) antibody heavy chains comprises in the first constant heavy chain domain (CH1) a glutamic acid residue at position 147 (instead of the wild type lysine residue; K147E mutation) and a glutamic acid residue at position 213 (instead of the wild type lysine amino acid residue; K213E mutation) (numbering according to the Kabat EU index); An additional Fab fragment that specifically binds to a second antigen comprises a domain crossover such that the constant light domain (CL) and the constant heavy domain 1 (CH1) are replaced by each other; and The first antigen is human A-beta protein and the second antigen is human transferrin receptor.

[0013] In one embodiment, an additional Fab fragment is fused to the C-terminus of the heavy chain by a peptide linker.

[0014] In one embodiment, the N-terminus of the heavy chain variable domain of a Fab fragment is fused to the C-terminus of a full-length heavy chain or to the C-terminus of a peptide linker.

[0015] In one embodiment, a) the full-length heavy chain fused to the additional Fab fragment has as its C-terminal heavy chain amino acid residue the tripeptide LSP, the proline of which is fused via a peptide bond directly to the first amino acid residue of the additional Fab fragment or of a peptide linker; and b) The full length heavy chain, not fused to an additional Fab fragment, has the tripeptide LSP, or SPG, or PGK as the C-terminal heavy chain amino acid residue.

[0016] In one embodiment the (full length) antibody is: a) a full-length human antibody of subclass IgG1; b) a full-length human antibody of subclass IgG4; c) a full-length antibody of human subclass IgG1 with the mutations L234A, L235A, and P329G; d) A full-length antibody of human subclass IgG4 with the mutations S228P, L235E, and P329G; e) a full-length antibody of human subclass IgG1 with the mutations L234A, L235A, and P329G in both heavy chains, and the mutations T366W and S354C in one heavy chain, and the mutations T366S, L368A, Y407V, and Y349C in each of the other heavy chains; f) A full-length antibody of human subclass IgG4 with the mutations S228P, L235E, and P329G in both heavy chains, and the mutations T366W and S354C in one heavy chain, and the mutations T366S, L368A, Y407V, and Y349C in each of the other heavy chains; g) a full-length antibody of human subclass IgG1 with the mutations L234A, L235A, P329G, I253A, H310A, and H435A in both heavy chains, and the mutations T366W and S354C in one heavy chain, and the mutations T366S, L368A, Y407V, and Y349C in the respective other heavy chain, or h) A full-length antibody of human subclass IgG1 with the mutations L234A, L235A, P329G, M252Y, S254T, and T256E in both heavy chains, and the mutations T366W and S354C in one heavy chain, and the mutations T366S, L368A, Y407V, and Y349C in the respective other heavy chain.

[0017] In one embodiment the (full length) antibody is: a) a full-length human antibody of subclass IgG1; b) a full-length human antibody of subclass IgG4; c) a full-length antibody of human subclass IgG1 with the mutations L234A, L235A, and P329G; d) A full-length antibody of human subclass IgG4 with the mutations S228P, L235E, and P329G; e) a full-length antibody of human subclass IgG1 with the mutations L234A, L235A, and P329G in both heavy chains and the mutations i) T366W, and ii) S354C or Y349C in one heavy chain and i) T366S, L368A, and Y407V, and ii) Y349C or S354C in each other heavy chain; f) a full-length antibody of human subclass IgG4 with the mutations S228P, L235E, and P329G in both heavy chains and the mutations i) T366W, and ii) S354C or Y349C in one heavy chain and the mutations i) T366S, L368A, and Y407V, and ii) Y349C or S354C in each other heavy chain; g) a full-length antibody of human subclass IgG1 with the mutations L234A, L235A, P329G, I253A, H310A, and H435A in both heavy chains, and the mutations i) T366W, and ii) S354C or Y349C in one heavy chain, and the mutations i) T366S, L368A, and Y407V, and ii) Y349C or S354C in each other heavy chain; h) a full-length antibody of human subclass IgG1 with the mutations L234A, L235A, P329G, M252Y, S254T, and T256E in both heavy chains, and the mutations i) T366W, and ii) S354C or Y349C in one heavy chain, and the mutations i) T366S, L368A, and Y407V, and ii) Y349C or S354C in each other heavy chain, or A full-length antibody of human subclass IgG1 with the mutations i) L234A, L235A, P329G, H310A, H433A, and Y436A in both heavy chains, and the mutations i) T366W, and ii) S354C or Y349C in one heavy chain, and the mutations i) T366S, L368A, and Y407V, and ii) Y349C or S354C in each other heavy chain.

[0018] In one embodiment, the additional Fab fragment is fused to the C-terminus of the heavy chain comprising the mutation T366W or the C-terminus of the heavy chain comprising the mutations T366S, L368A and Y407V.

[0019] In one embodiment, The full length antibody is of human subclass IgG1 with the mutations L234A, L235A, and P329G in both heavy chains, and the mutations T366W and S354C in one heavy chain, and the mutations T366S, L368A, Y407V, and Y349C in each of the other heavy chains; and An additional Fab fragment is fused to the C-terminus of the heavy chain containing the mutation T366W or the C-terminus of the heavy chain containing the mutations T366S, L368A, and Y407V.

[0020] In one embodiment of all aspects, the human A-beta binding site comprises the VH sequence of SEQ ID NO: 18 (including post-translational modifications of that sequence) and the VL sequence of SEQ ID NO: 19 (including post-translational modifications of that sequence).

[0021] In one embodiment, the human transferrin binding site comprises the VH sequence of SEQ ID NO: 20 (including post-translational modifications of that sequence) and the VL sequence of SEQ ID NO: 21 (including post-translational modifications of that sequence).

[0022] In one embodiment, the bispecific antibody comprises: i) a light chain with an amino acid sequence having 70% or more sequence identity to SEQ ID NO: 01; ii) a heavy chain with an amino acid sequence having 70% or more sequence identity to SEQ ID NO: 02; iii) a light chain with an amino acid sequence having 70% or more sequence identity to SEQ ID NO:03; and iv) a heavy chain Fab fragment with an amino acid sequence having 70% or more sequence identity to SEQ ID NO:04. In that regard, SEQ ID NO: 01 is the amino acid sequence [ka] having SEQ ID NO: 02 is the amino acid sequence [ka] having SEQ ID NO: 03 is the amino acid sequence [ka] and SEQ ID NO: 04 is the amino acid sequence [ka] has.

[0023] One embodiment reported herein is a bispecific antibody comprising a (full length) light chain having the amino acid sequence of SEQ ID NO: 01, a (full length) heavy chain having the amino acid sequence of SEQ ID NO: 02, a (full length) light chain having the amino acid sequence of SEQ ID NO: 03, and an antibody Fab fragment comprising the amino acid sequence of SEQ ID NO: 04.

[0024] In one embodiment, the bispecific antibody is monoclonal.

[0025] One aspect reported herein is an isolated nucleic acid encoding a bispecific antibody as reported herein.

[0026] One embodiment as reported herein is a host cell comprising a nucleic acid as reported herein encoding a bispecific antibody as reported herein.

[0027] One embodiment reported herein is a method for producing a bispecific antibody as reported herein, comprising the steps of: a) culturing a host cell as described herein so as to produce a bispecific antibody; and b) recovering the bispecific antibody from the cells or culture medium, thereby producing the bispecific antibody as reported herein.

[0028] One aspect reported herein is an immunoconjugate comprising a bispecific antibody as reported herein and a cytotoxic agent.

[0029] One aspect reported herein is a pharmaceutical formulation comprising a bispecific antibody as reported herein and a pharma- ceutical acceptable carrier.

[0030] One aspect reported herein is an antibody as reported herein for use as a medicament.

[0031] One embodiment reported herein is a bispecific antibody reported herein for use in treating Alzheimer's disease.

[0032] One embodiment reported herein is a bispecific antibody reported herein for use in inhibiting / slowing down the formation of plaques in the brain.

[0033] One aspect reported herein is a bispecific antibody reported herein for use in degrading β-amyloid plaques.

[0034] One aspect reported herein is the use of a bispecific antibody as reported herein in the manufacture of a medicament.

[0035] In one embodiment, the medicament is for the treatment of an amyloid disorder.

[0036] In one embodiment, the medicament is for the prevention and / or treatment of a disease associated with amyloid formation and / or amyloid plaque formation. In one embodiment, the disease is selected from the group consisting of dementia, Alzheimer's disease, motor neuropathy, Down's syndrome, Creutzfeldt-Jakob disease, Hereditary Cerebral Hemorrhage with Amyloidosis of the Dutch Type, Parkinson's Disease, HIV-associated dementia, ALS or neurological disorders associated with aging. In a preferred embodiment, the medicament is for the treatment of Alzheimer's disease.

[0037] In one embodiment, the medicament is for inhibiting / slowing down the formation of plaques in the brain, hi one embodiment, the medicament is for the degradation of beta amyloid plaques.

[0038] One embodiment reported herein is a method of treating an individual having a disease associated with amyloid formation and / or amyloid plaque formation comprising administering to the individual an effective amount of a bispecific antibody reported herein.

[0039] One embodiment reported herein is a method of treating an individual with Alzheimer's disease comprising administering to the individual an effective amount of a bispecific antibody reported herein.

[0040] One embodiment reported herein is a method for the degradation of beta amyloid plaques in the brain of an individual comprising administering to the individual an effective amount of a bispecific antibody reported herein to degrade beta amyloid plaques in the brain.

[0041] One embodiment reported herein is a method of inhibiting / slowing down the formation of plaques in the brain of an individual comprising administering to the individual an effective amount of a bispecific antibody reported herein to inhibit / slow down the formation of plaques in the brain.

[0042] DETAILED DESCRIPTION OF EMBODIMENTS OF THE PRESENTINVENTION Knob into hole dimerization modules and their use in antibody engineering are described in Carter P.; Ridgway JBB; Presta LG: Immunotechnology, Volume 2, Number 1, February 1996, pp. 73-73. An additional disulfide bridge in the CH3 domain is reported in Merchant, AM, et al., Nat. Biotechnol. 16 (1998) 677-681.

[0043] General information regarding the nucleotide sequences of human immunoglobulin light and heavy chains is given in: Kabat, EA, et al., Sequences of Proteins of Immunological Interest, 5th ed., Public Health Service, National Institutes of Health, Bethesda, MD (1991).

[0044] As used herein, the amino acid positions of all heavy and light chain constant regions and domains are numbered according to the Kabat numbering system as set forth in Kabat, et al., Sequences of Proteins of Immunological Interest, 5th ed., Public Health Service, National Institutes of Health, Bethesda, MD (1991), and is referred to herein as the "Kabat numbering." Specifically, the Kabat numbering system of Kabat, et al., Sequences of Proteins of Immunological Interest, 5th ed., Public Health Service, National Institutes of Health, Bethesda, MD (1991) (see pages 647-660) is used for the light chain constant domains CL of the kappa and lambda isotypes, and the Kabat EU index numbering system (see pages 661-723) is used for the constant heavy chain domains (CH1, hinge, CH2, and CH3, further defined herein by reference to "Kabat EU index numbering").

[0045] I. Definition "Blood-brain barrier" or "BBB" refers to the physiological barrier between the peripheral circulation and the brain and spinal cord formed by tight junctions in the brain capillary endothelial cell membrane, resulting in a tight barrier that limits the transport of even very small molecules, such as urea (60 daltons), into the brain. The BBB in the brain, the blood-spinal cord-barrier in the spinal cord, and the blood-retina-barrier in the retina are continuous capillary barriers in the CNS and are collectively referred to herein as the blood-brain barrier or BBB. The BBB also encompasses the blood-CSF barrier (choroid plexus), which is composed of ependymal cells rather than capillary endothelial cells.

[0046] The terms "anti-human A-beta antibody" and "antibody that specifically binds to human A-beta" refer to an antibody that is capable of binding to human A-beta peptide with sufficient affinity such that the antibody is useful as a diagnostic and / or therapeutic agent in targeting A-beta peptide.

[0047] Note that human A-beta has several naturally occurring forms, whereby the human forms are referred to as Aβ39, Aβ40, Aβ41, Aβ42, and Aβ43. The most prominent form, Aβ42, has the amino acid sequence of SEQ ID NO:05. Aβ41, Aβ40, Aβ39 are missing the C-terminal amino acids A, IA, and VIA, respectively. The Aβ43 form contains an additional threonine residue at the C-terminus of SEQ ID NO:05. In one embodiment, the human A-beta protein has the amino acid sequence of SEQ ID NO:05.

[0048] Thus, the term also encompasses antibodies that bind truncated fragments of human A-beta polypeptide.

[0049] "Central nervous system" or "CNS" refers to the complex of nervous tissue that controls bodily functions and includes the brain and spinal cord.

[0050] A "blood-brain barrier receptor" (abbreviated herein as "BBBR") is an extracellular membrane-bound receptor protein expressed on brain endothelial cells that is capable of transporting molecules across the BBB or is used to transport exogenously administered molecules. Examples of BBBRs herein include transferrin receptor (TfR), insulin receptor, insulin-like growth factor receptor (IGF-R), low-density lipoprotein receptor (including, but not limited to, low-density lipoprotein receptor-related protein 1 (LRP1) and low-density lipoprotein receptor-related protein 8 (LRP8)), and heparin-binding epidermal growth factor-like growth factor (HB-EGF). One preferred BBBR is the transferrin receptor (TfR).

[0051] The "transferrin receptor" ("TfR") is a transmembrane glycoprotein (molecular weight approximately 180,000 Da) composed of two disulfide-linked subunits (each of apparent molecular weight approximately 90,000 Da) that is involved in iron uptake in vertebrates. In one embodiment, the TfR described herein is a human TfR, e.g., comprising the amino acid sequence of Schneider et al. (Nature 311 (1984) 675-678). In one embodiment, the human transferrin receptor has the amino acid sequence of SEQ ID NO:22.

[0052] A "multispecific antibody" refers to an antibody that has binding specificities for at least two different epitopes on the same antigen or two different antigens. An exemplary multispecific antibody may bind to both BBBR and brain antigens. Multispecific antibodies can be prepared as full-length antibodies or antibody fragments (e.g., F(ab')2 bispecific antibodies) or combinations thereof (e.g., full-length antibody plus additional scFv or Fab fragments). Engineered antibodies with two, three or more (e.g., four) functional antigen binding sites have also been reported (see, e.g., US 2002 / 0004587 A1).

[0053] An "acceptor human framework" for purposes herein is a framework that comprises the amino acid sequence of a light chain variable domain (VL) framework or a heavy chain variable domain (VH) framework derived from a human immunoglobulin framework or a human consensus framework as defined below. An acceptor human framework "derived" from a human immunoglobulin framework or a human consensus framework may comprise the same amino acid sequence thereof, or it may comprise amino acid sequence changes. In some embodiments, the number of amino acid changes is 10 or less, 9 or less, 8 or less, 7 or less, 6 or less, 5 or less, 4 or less, 3 or less, or 2 or less. In some embodiments, the VL acceptor human framework is identical in sequence to the VL human immunoglobulin framework sequence or the human consensus framework sequence.

[0054] "Affinity" refers to the strength of the sum of non-covalent interactions between a single binding site of a molecule (e.g., an antibody) and its binding partner (e.g., an antigen). Unless otherwise specified, as used herein, "binding affinity" refers to the intrinsic binding affinity that reflects a 1:1 interaction between members of a binding pair (e.g., an antibody and an antigen). The affinity for a molecule X and its partner Y can generally be expressed by the dissociation constant (kd). Affinity can be measured by common methods known in the art, including those described herein.

[0055] An "affinity matured" antibody refers to an antibody with one or more alterations in one or more hypervariable regions (HVRs) (compared to a parent antibody lacking such alterations), which alterations result in an improvement in the affinity of the antibody for the antigen.

[0056] The term "antibody" herein is used in the broadest sense and encompasses a variety of antibody structures, including, but not limited to, monoclonal antibodies, polyclonal antibodies, and multispecific antibodies (e.g., bispecific antibodies), so long as they exhibit the desired antigen-binding activity.

[0057] The term "antibody-dependent cellular cytotoxicity (ADCC)" refers to a function mediated by Fc receptor binding and the lysis of target cells by antibodies as reported herein in the presence of effector cells. In one embodiment, ADCC is measured by treating a preparation of CD19-expressing erythroid cells (e.g., K562 cells expressing recombinant human CD19) with an antibody as reported herein in the presence of effector cells, such as freshly isolated PBMCs (peripheral blood mononuclear cells) or effector cells purified from buffy coats, such as monocytes or NK (natural killer) cells. Target cells are 51 The labeled cells are then incubated with effector cells and the supernatant is purified by ELISA to detect the released 51 The antibodies are analyzed for Cr. Controls include incubation of target endothelial cells with effector cells (without antibody). The ability of the antibodies to induce the early steps of mediating ADCC is examined by measuring their binding to Fcγ receptor expressing cells, such as cells recombinantly expressing FcγRI and / or FcγRIIA or NK cells (which inherently express FcγRIIIA). In a preferred embodiment, binding to FcγR on NK cells is measured.

[0058] "Antibody fragment" refers to a molecule other than an intact antibody that contains a portion of an intact antibody that binds to the antigen to which the intact antibody binds. Examples of antibody fragments include, but are not limited to, Fv, Fab, Fab', Fab'-SH, F(ab')2; diabodies; linear antibodies; single-chain antibody molecules (e.g., scFv); and multispecific antibodies formed from antibody fragments.

[0059] The term "chimeric" antibody refers to an antibody in which a portion of the heavy and / or light chain is derived from a particular source or species, while the remaining portions of the heavy and / or light chain are derived from a different source or species.

[0060] The "class" of an antibody refers to the type of constant domain or constant region carried by its heavy chain. There are five major classes of antibodies: IgA, IgD, IgE, IgG, and IgM. Some of these can be further divided into subclasses (isotypes) (e.g., IgG1, IgG2, IgG3, IgG4, IgA1, and IgA2). The heavy-chain constant domains that correspond to the different classes of immunoglobulins are called α, δ, ε, γ, and μ, respectively.

[0061] The term "cytotoxic agent," as used herein, refers to a substance that inhibits or prevents the function of cells and / or causes cell death or destruction. Cytotoxic agents include radioisotopes (e.g., At 211 , I 131 , I 125 , Y 90 , Re 186 , Re 188 , Sm 153 , Bi 212 , P 32 , Pb 212 and radioactive isotopes of Lu); chemotherapeutic agents or drugs (e.g., methotrexate, adriamicin, vinca alkaloids (vincristine, vinblastine, etoposide), doxorubicin, melphalan, mitomycin C, chlorambucil, daunorubicin, or other intercalating agents); growth inhibitory agents; enzymes and fragments thereof, such as nucleases; antibiotics; toxins, such as small molecule toxins or enzymatically active toxins of bacterial, fungal, plant, or animal origin, including fragments and / or variants thereof; and various anti-tumor or anti-cancer agents disclosed below.

[0062] The term "complement-dependent cytotoxicity (CDC)" refers to the lysis of cells induced by the antibodies reported herein in the presence of complement. In one embodiment, CDC is measured by treating human endothelial cells expressing CD19 with the antibodies reported herein in the presence of complement. The cells are, in one embodiment, labeled with calcein. CDC is found when the antibody induces lysis of 20% or more of the target cells at a concentration of 30 μg / mL. Binding to the complement factor C1q can be measured in an ELISA. In such an assay, as a rule, an ELISA plate is coated with a range of concentrations of the antibody plus purified human C1q or human serum. C1q binding is detected by an antibody against C1q followed by a peroxidase-labeled conjugate. Detection of binding (maximum binding Bmax) is measured as optical density at 405 nm (OD405) for the peroxidase substrate ABTS® (2,2'-azino-di-[3-ethylbenzthiazoline-6-sulfonate (6)]).

[0063] "Effector functions" refer to those biological activities attributable to the Fc region of an antibody, which vary with antibody class. Examples of antibody effector functions include C1q binding and complement-dependent cytotoxicity (CDC); Fc receptor binding; antibody-dependent cell-mediated cytotoxicity (ADCC); phagocytosis; downregulation of cell surface receptors (e.g., B cell receptor); and B cell activation.

[0064] Fc receptor binding-dependent effector functions can be mediated by the interaction of the Fc region of an antibody with Fc receptors (FcRs), specialized cell surface receptors on hematopoietic cells. Fc receptors belong to the immunoglobulin superfamily and have been shown to mediate both the removal of antibody-coated pathogens by phagocytosis of immune complexes via antibody-dependent cell-mediated cytotoxicity (ADCC) and the lysis of corresponding antibody-coated red blood cells and various other cellular targets (e.g., tumor cells) (see, e.g., Van de Winkel, JG and Anderson, CL, J. Leukoc. Biol. 49 (1991) 511-524). FcRs are defined by their specificity for immunoglobulin isotypes: Fc receptors for IgG antibodies are referred to as FcγRs. Fc receptor binding is described, for example, in Ravetch, JV and Kinet, JP, Annu. Rev. Immunol. 9 (1991) 457-492; Capel, PJ, et al., Immunomethods 4 (1994) 25-34; de Haas, M., et al., J. Lab. Clin. Med. 126 (1995) 330-341; and Gessner, JE, et al., Ann. Hematol. 76 (1998) 231-248.

[0065] Cross-linking of receptors for the Fc region of IgG antibodies (FcγR) triggers a wide range of effector functions including phagocytosis, antibody-dependent cellular cytotoxicity, and release of inflammatory mediators, as well as regulation of immune complex clearance and antibody production. In humans, three classes of FcγR have been characterized: - FcγRI (CD64) binds monomeric IgG with high affinity and is expressed on macrophages, monocytes, neutrophils, and eosinophils. Modifications of the Fc region IgG at least amino acid residues E233-G236, P238, D265, N297, A327, and P329 (EU index Kabat numbering) reduce binding to FcγRI. Substitution of IgG2 residues at positions 233-236 with IgG1 and IgG4 reduces binding to FcγRI by 10. 3 2-fold decrease in human monocyte responses to antibody-sensitized red blood cells and abolishment of the human monocyte response to antibody-sensitized red blood cells (Armour, KL, et al., Eur. J. Immunol. 29 (1999) 2613-2624). - FcγRII (CD32) binds complexed IgG with medium to low affinity and is widely expressed. This receptor can be divided into two subtypes, FcγRIIA and FcγRIIB. FcγRIIA is found on many cells involved in killing (e.g. macrophages, monocytes, neutrophils) and appears to be able to activate the killing process. FcγRIIB appears to play a role in inhibitory processes and is found on B cells, macrophages, as well as mast cells and eosinophils. On B cells it appears to function to suppress further immunoglobulin production and isotype switching, for example to the IgE class. On macrophages, FcγRIIB acts to inhibit phagocytosis mediated through FcγRIIA. On eosinophils and mast cells, the B form may serve to suppress activation of these cells through IgE binding to its separate receptor. Reduced binding for FcγRIIA is found, for example, for antibodies comprising an IgG Fc region with mutations in at least one of amino acid residues E233-G236, P238, D265, N297, A327, P329, D270, Q295, A327, R292, and K414 (numbering according to the EU index of Kabat). - FcγRIII (CD16) binds IgG with moderate to low affinity and exists as two types: FcγRIIIA is found on NK cells, macrophages, eosinophils, and some monocytes and T cells, and mediates ADCC; FcγRIIIB is highly expressed on neutrophils. Reduced binding to FcγRIIIA is found, for example, for antibodies that comprise an IgG Fc region with mutations at least one of the amino acid residues E233-G236, P238, D265, N297, A327, P329, D270, Q295, A327, S239, E269, E293, Y296, V303, A327, K338, and D376 (numbering according to the EU index of Kabat).

[0066] Mapping of binding sites on human IgG1 for Fc receptors, the mutation sites described above, and methods for measuring binding to FcγRI and FcγRIIA are described in Shields, RL, et al. J. Biol. Chem. 276 (2001) 6591-6604.

[0067] An "effective amount" of an agent (eg, a pharmaceutical formulation) refers to an amount effective, at dosages and for periods of time necessary, to achieve the desired therapeutic or prophylactic result.

[0068] The term "Fc receptor" as used herein refers to an activating receptor characterized by the presence of a cytoplasmic ITAM sequence associated with the receptor (see, e.g., Ravetch, JV and Bolland, S., Annu. Rev. Immunol. 19 (2001) 275-290). Such receptors are FcγRI, FcγRIIA, and FcγRIIIA. The term "non-binding of FcγR" indicates that at an antibody concentration of 10 μg / mL, the binding of the antibodies reported herein to NK cells is 10% or less than the binding found for the anti-OX40L antibody LC.001 reported in WO 2006 / 029879.

[0069] IgG4 shows reduced FcR binding, whereas antibodies of other IgG subclasses show strong binding. However, Pro238, Asp265, Asp270, Asn297 (deletion of Fc sugar), Pro329, as well as 234, 235, 236 and 237, Ile253, Ser254, Lys288, Thr307, Gln311, Asn434, and His435 are residues that, when altered, provide reduced FcR binding (Shields, RL, et al. J. Biol. Chem. 276 (2001) 6591-6604; Lund, J., et al., FASEB J. 9 (1995) 115-119; Morgan, A., et al., Immunology 86 (1995) 319-324; and EP 0 307 434). In one embodiment, the antibody as reported herein is of IgG1 or IgG2 subclass and comprises the mutations PVA236, GLPSS331 and / or L234A / L235A. In one embodiment, the antibody as reported herein is of IgG4 subclass and comprises the mutation L235E. In one embodiment, the antibody further comprises the mutation S228P.

[0070] The term "Fc region" is used herein to define a C-terminal region of an immunoglobulin heavy chain that comprises at least a portion of the constant region. This term includes native sequence Fc regions and variant Fc regions. In one embodiment, a human IgG heavy chain Fc region extends from Cys226, or from Pro230, to the carboxyl terminus of the heavy chain. However, the C-terminal lysine (Lys447) of the Fc region may be present or absent. Unless otherwise specified herein, the numbering of amino acid residues in an Fc region or constant region is according to the EU numbering system (also referred to as the EU index), as described in Kabat, EA et al., Sequences of Proteins of Immunological Interest, 5th ed., Public Health Service, National Institutes of Health, Bethesda, MD (1991), NIH Publication 91-3242.

[0071] The antibodies reported herein comprise, as Fc region, an Fc region of, in one embodiment, human origin. In one embodiment, the Fc region comprises all parts of the human constant region. The Fc region of an antibody is directly involved in complement activation, C1q binding, C3 activation, and Fc receptor binding. Although the effect of an antibody on the complement system depends on the specific conditions, binding to C1q occurs through a defined binding site in the Fc region. Such binding sites are known in the state of the art and are described, for example, in Lukas, TJ, et al., J. Immunol. 127 (1981) 2555-2560; Brunhouse, R., and Cebra, JJ, Mol. Immunol. 16 (1979) 907-917; Burton, DR, et al., Nature 288 (1980) 338-344; Thommesen, JE, et al., Mol. Immunol. 37 (2000) 995-1004; Idusogie, EE, et al., J. Immunol. 164 (2000) 4178-4184; Hezareh, M., et al., J. Virol. 75 (2001) 12161-12168; Morgan, A., et al., Immunology 86 (1995) 319-324; and EP 0 307 434. Such binding sites are, for example, L234, L235, D270, N297, E318, K320, K322, P331, and P329 (numbering according to the EU index of Kabat; unless otherwise specified herein, the numbering of amino acid residues in the Fc region or constant region is according to the EU numbering system (also called EU index) as described in Kabat, EA et al., Sequences of Proteins of Immunological Interest, 5th ed., Public Health Service, National Institutes of Health, Bethesda, MD (1991), NIH Publication 91-3242).Antibodies of the subclasses IgG1, IgG2, and IgG3 usually exhibit complement activation, C1q binding, and C3 activation, whereas IgG4 does not activate the complement system, does not bind C1q, and does not activate C3. "Fc region of an antibody" is a term well known to those skilled in the art and is defined based on papain cleavage of an antibody. In one embodiment, the Fc region is a human Fc region. In one embodiment, the Fc region is a human IgG4 subclass containing the mutations S228P and / or L235E (numbering according to EU index of Kabat). In one embodiment, the Fc region is a human IgG1 subclass containing the mutations L234A and L235A (numbering according to EU index of Kabat).

[0072] "Framework" or "FR" refers to variable domain residues other than hypervariable region (HVR) residues. The FR of a variable domain generally consists of four FR domains, FR1, FR2, FR3, and FR4. Thus, the HVR and FR sequences generally appear in the following order in VH (or VL): FR1-H1(L1)-FR2-H2(L2)-FR3-H3(L3)-FR4.

[0073] The terms "full-length antibody", "intact antibody" and "complete antibody" are used interchangeably herein and refer to an antibody having a structure substantially similar to a native antibody structure or having a heavy chain including an Fc region as defined herein. A "full-length antibody" is an antibody comprising light and heavy chain antigen-binding variable regions (VL, VH) and a light chain constant domain (CL) and heavy chain constant domains, CH1, CH2 and CH3. The constant domains may be native sequence constant domains (e.g., human native sequence constant domains) or amino acid sequence variants thereof. More specifically, a full-length antibody comprises two antibody light chains (each comprising a light chain variable domain and a light chain constant domain) and two antibody heavy chains (each comprising a heavy chain variable domain, a hinge region, and heavy chain constant domains CH1, CH2 and CH3). The C-terminal amino acid residues K or GK may be present in the two antibody heavy chains of a full-length antibody or may not be independent of each other. Full length antibodies may also include amino acid additions, mutations and deletions within domains, but not entire domain deletions.

[0074] The terms "host cell," "host cell line," and "host cell culture" are used interchangeably to refer to cells into which exogenous nucleic acid has been introduced, including the progeny of such cells. Host cells include "transformants" and "transformed cells," which include the primary transformed cell and its progeny derived therefrom, regardless of the number of passages. The progeny may not be completely identical in nucleic acid content to the parent cell, but may contain mutations. Mutant progeny that have the same function or biological activity as screened for or selected for in the originally transformed cell are included herein.

[0075] A "human consensus framework" is a framework that represents the most commonly occurring amino acid residues in a selection of human immunoglobulin VL or VH framework sequences. Typically, the selection of human immunoglobulin VL or VH sequences is from a subgroup of variable domain sequences. Typically, the subgroup of sequences is as in Kabat, EA et al., Sequences of Proteins of Immunological Interest, 5th ed., Bethesda MD (1991), NIH Publication 91-3242, Vols. 1-3. In one embodiment, for VL, the subgroup is subgroup kappa I as in Kabat et al., supra. In one embodiment, for VH, the subgroup is subgroup III as in Kabat et al., supra.

[0076] A "humanized" antibody refers to a chimeric antibody that comprises amino acid residues from non-human HVRs and amino acid residues from human FRs. In certain embodiments, a humanized antibody comprises substantially all of at least one, and typically two, variable domains, in which all or substantially all of the HVRs (e.g., CDRs) correspond to those of a non-human antibody and all or substantially all of the FRs correspond to those of a human antibody. A humanized antibody may optionally comprise at least a portion of an antibody constant region derived from a human antibody. A "humanized form" of an antibody (e.g., a non-human antibody) refers to an antibody that has undergone humanization.

[0077] The term "hypervariable region" or "HVR", as used herein, refers to each of the regions of an antibody variable domain that comprise stretches of amino acid residues that are hypervariable in sequence ("complementarity determining regions" or "CDRs") and / or that form structurally defined loops ("hypervariable loops") and / or contain antigen contact residues ("antigen contacts"). Generally, antibodies comprise six HVRs; three in VH (H1, H2, H3) and three in VL (L1, L2, L3).

[0078] HVR includes: (a) hypervariable loops occurring at amino acid residues 26-32 (L1), 50-52 (L2), 91-96 (L3), 26-32 (H1), 53-55 (H2), and 96-101 (H3) (Chothia, C. and Lesk, A. M., J. Mol. Biol. 196 (1987) 901-917); (b) CDRs occurring at amino acid residues 24-34 (L1), 50-56 (L2), 89-97 (L3), 31-35b (H1), 50-65 (H2), and 95-102 (H3) (Kabat, EA et al., Sequences of Proteins of Immunological Interest, 5th ed. Public Health Service, National Institutes of Health, Bethesda, MD(1991), NIH Publication 91-3242); (c) antigen contacts occurring at amino acid residues 27c-36 (L1), 46-55 (L2), 89-96 (L3), 30-35b (H1), 47-58 (H2), and 93-101 (H3) (MacCallum et al. J. Mol. Biol. 262: 732-745 (1996)); and (d) a combination of (a), (b), and / or (c), comprising amino acid residues 46-56 (L2), 47-56 (L2), 48-56 (L2), 49-56 (L2), 26-35 (H1), 26-35b (H1), 49-65 (H2), 93-102 (H3), and 94-102 (H3).

[0079] Unless otherwise indicated, HVR residues and other residues in the variable domain (e.g., FR residues) are numbered herein according to Kabat (supra).

[0080] An "immunoconjugate" is an antibody conjugated to one or more heterologous molecules, including, but not limited to, cytotoxic agents.

[0081] An "individual" or "subject" is a mammal. Mammals include, but are not limited to, domestic animals (e.g., cows, sheep, cats, dogs, and horses), primates (e.g., humans and non-human primates, such as monkeys), rabbits, and rodents (e.g., mice and rats). In certain embodiments, the individual or subject is a human.

[0082] An "isolated" antibody is one that has been separated from a component of its natural environment. In some embodiments, the antibody is purified to greater than 95% or 99% purity, for example, as determined by electrophoresis (e.g., SDS-PAGE, isoelectric focusing (IEF), capillary electrophoresis) or chromatography (e.g., ion exchange or reverse phase HPLC). For a review of methods for assessing antibody purity, see, e.g., Flatman, S. et al., J. Chrom. B 848 (2007) 79-87.

[0083] An "isolated" nucleic acid refers to a nucleic acid molecule that has been separated from a component of its natural environment. Isolated nucleic acid includes a nucleic acid molecule contained in a cell that ordinarily contains the nucleic acid molecule, but where the nucleic acid molecule is present extrachromosomally or at a chromosomal location that is different from its natural chromosomal location.

[0084] An "isolated nucleic acid encoding an anti-human A-beta / human transferrin receptor antibody" refers to one or more nucleic acid molecules encoding the antibody heavy and light chains (or fragments thereof), comprising such nucleic acid molecules in a single vector or separate vectors, and wherein such nucleic acid molecules are present in one or more locations in a host cell.

[0085] As used herein, the term "monoclonal antibody" refers to an antibody obtained from a population of substantially homogeneous antibodies, i.e., the individual antibodies comprising the population are identical and / or bind the same epitope, except for possible variant antibodies (e.g., including naturally occurring mutations or arising during production of the monoclonal antibody preparation), such variants being generally present in minor amounts. In contrast to polyclonal antibody preparations, which typically include different antibodies directed against different determinants (epitopes), each monoclonal antibody of a polyclonal antibody preparation is directed against a single determinant on the antigen. Thus, the modifier "monoclonal" indicates the character of the antibody as being obtained from a substantially homogeneous population of antibodies, and should not be construed as requiring production of the antibody by any particular method. For example, monoclonal antibodies to be used in accordance with the present invention may be made by a variety of techniques, including, but not limited to, hybridoma methods, recombinant DNA methods, phage display methods, and methods utilizing transgenic animals containing all or portions of the human immunoglobulin loci, and such methods, as well as other exemplary methods for making monoclonal antibodies, are described herein.

[0086] "Naked antibody" refers to an antibody that is not conjugated to a heterologous moiety (e.g., a cytotoxic moiety) or radiolabel. The naked antibody may be present in a pharmaceutical formulation.

[0087] "Native antibodies" refer to naturally occurring immunoglobulin molecules with variable structures. For example, native IgG antibodies are heterotetrameric glycoproteins of about 150,000 daltons, composed of two identical light chains and two identical heavy chains that are disulfide-bonded. From the N-terminus to the C-terminus, each heavy chain has a variable region (VH) (also called the variable heavy domain or the heavy chain variable domain), followed by three constant domains (CH1, CH2, and CH3), which position the hinge region between the first and second constant domains. Similarly, from the N-terminus to the C-terminus, each light chain has a variable region (VL) (also called the variable light domain or the light chain variable domain), followed by a constant light domain (CL). The light chain of an antibody can be assigned to one of two types, called kappa (κ) and lambda (λ), based on the amino acid sequence of its constant domain.

[0088] The term "package insert" is used to refer to instructions typically included in commercial packaging of a therapeutic product, which may contain information regarding indications, usage, dosage, administration, concomitant treatments, contraindications, and / or warnings regarding the use of such therapeutic product.

[0089] "Percent (%) amino acid sequence identity" with respect to a reference polypeptide sequence is defined as the percentage of amino acid residues in a candidate sequence that are identical to the amino acid residues in the reference polypeptide sequence after aligning the sequences, introducing gaps (if necessary), and achieving the highest percent sequence identity (not considering any conservative substitutions as part of the sequence identity). Alignment for purposes of determining percent amino acid sequence identity can be achieved in a variety of ways within the art, for example, using publicly available computer software such as BLAST, BLAST-2, ALIGN, or Megalign (DNASTAR) software. Those skilled in the art can determine appropriate parameters for aligning sequences, including any algorithms required to achieve the highest alignment over the entire length of the sequences being compared. For purposes herein, however, % amino acid sequence identity values ​​are generated using the sequence comparison computer program ALIGN-2. The ALIGN-2 sequence comparison computer program was created by Genentech, Inc., whose source code has been filed with user documentation at the US Copyright Office, Washington DC, 20559, where it is registered under US Copyright Registration No. TXU510087. The ALIGN-2 program is publicly available from Genentech, Inc. (South San Francisco, CA) or can be compiled from the source code. The ALIGN-2 program must be compiled for use on a UNIX operating system (including Digital UNIX V4.0D). All sequence comparison parameters are set by the ALIGN-2 program and are not varied.

[0090] In situations where ALIGN-2 is used for amino acid sequence comparison, the % amino acid sequence identity of a given amino acid sequence A to, with, or against a given amino acid sequence B (alternatively, it can be expressed as a given amino acid sequence A having or containing a particular % amino acid sequence identity to, with, or against a given amino acid sequence B) is calculated as follows: 100 x fraction X / Y where X is the number of amino acid residues scored as identical matches by the sequence alignment program ALIGN-2 in that program's alignment of A and B, and where Y is the total number of amino acid residues in B. It will be understood that if the length of amino acid sequence A is not equal to the length of amino acid sequence B, then the % amino acid sequence identity of A to B will not be equal to the % amino acid sequence identity of B to A. Unless otherwise specified, all % amino acid sequence identity values ​​used herein are obtained using the ALIGN-2 computer program as described in the immediately preceding paragraph.

[0091] The term "pharmaceutical formulation" refers to a preparation that is in a form that allows the biological activity of the active ingredients contained therein to be effective and that does not contain additional ingredients that are unacceptably toxic to a subject to which the formulation may be administered.

[0092] "Pharmaceutically acceptable carrier" refers to an ingredient in a pharmaceutical formulation, other than an active ingredient, that is non-toxic to a subject. Pharmaceutically acceptable carriers include, but are not limited to, buffers, excipients, stabilizers, or preservatives.

[0093] As used herein, "treatment" (and grammatical variations thereof, such as "treat" or "treating") refers to clinical intervention in an attempt to alter the natural course of the individual being treated, and can be performed for prophylaxis or during the course of clinical pathology. Desirable effects of treatment include, but are not limited to, prevention of disease onset or recurrence, alleviation of symptoms, attenuation of any direct or indirect pathological outcome of the disease, prevention of metastasis, reduction in the rate of disease progression, amelioration or palliation of the disease state, and remission or improved prognosis. In some embodiments, the antibodies reported in this invention are used to delay disease onset or slow disease progression.

[0094] The term "variable region" or "variable domain" refers to the domain of an antibody's heavy or light chain that is involved in the binding of the antibody to its antigen. The variable domains of the heavy and light chains (VH and VL, respectively) of natural antibodies generally have similar structures, with each domain containing four conserved framework regions (FR) and three hypervariable regions (HVR) (see, e.g., Kindt, TJ et al. Kuby Immunology, 6th ed., WH Freeman and Co., NY (2007), page 91). A single VH or VL domain may be sufficient to confer antigen-binding specificity. Furthermore, antibodies that bind to a particular antigen may be isolated using a VH or VL domain from an antibody that binds the antigen to screen a library of complementary VL or VH domains, respectively. See, e.g., Portolano, S. et al., J. Immunol. 150 (1993) 880-887; Clackson, T. et al., Nature 352 (1991) 624-628.

[0095] The term "vector," as used herein, refers to a nucleic acid molecule capable of propagating another nucleic acid to which it is linked. The term includes vectors as self-replicating nucleic acid structures as well as vectors integrated into the genome of a host cell into which it is introduced. Certain vectors are capable of directing the expression of nucleic acids to which they are operatively linked. Such vectors are referred to herein as "expression vectors."

[0096] II. Compositions and Methods In one aspect, the invention is based, in part, on the discovery that the bispecific anti-human A-beta / human transferrin receptor antibodies reported herein have improved properties. In a particular embodiment, bispecific anti-human A-beta / human transferrin receptor antibodies are provided. The antibodies reported herein are useful, for example, for the diagnosis or treatment of Alzheimer's disease.

[0097] A. Exemplary Bispecific Anti-Human A-beta / Human Transferrin Receptor Antibodies In one aspect, the present invention provides an isolated bispecific antibody that binds to human A-beta and human transferrin receptor. The antibody is a bispecific antibody consisting of a full-length core antibody and a fused Fab fragment in which certain domains have been cross-swapped. Thus, the resulting bispecific antibody is asymmetric. Therefore, the bispecific antibody is produced using a heterodimerization technique called knob-into-hole, using a first heavy chain with a so-called knob mutation (HCknob) and a second heavy chain with a so-called hole mutation (HChole).

[0098] Antibody 0012 is also an embodiment of the present invention, and is composed of four polypeptides having the amino acid sequences of SEQ ID NOs:06-09.

[0099] Antibody 0012 is a bispecific antibody comprising: a) a full-length antibody comprising two pairs of full-length antibody light chains and full-length antibody heavy chains, wherein the binding site formed by each pair of full-length heavy chains and full-length light chains specifically binds to a first antigen; and b) one additional Fab fragment, in which the binding site of the additional Fab fragment specifically binds to a second antigen, is fused to the C-terminus of one heavy chain of the full-length antibody; each of the full-length antibody light chains comprises in the constant light domain (CL) the amino acid residue arginine at position 123 (instead of the wild-type glutamic acid residue; E123R mutation) and the amino acid residue lysine at position 124 (instead of the wild-type glutamine residue; Q124K mutation) (numbering according to Kabat); each of the full-length antibody heavy chains comprises in the first constant heavy chain domain (CH1) a glutamic acid residue at position 147 (instead of the wild-type lysine residue; K147E mutation) and a glutamic acid residue at position 213 (instead of the wild-type lysine amino acid residue; K213E mutation) (numbering according to the Kabat EU index); An additional Fab fragment that specifically binds to a second antigen comprises a domain crossover such that the light chain variable domain (VL) and the heavy chain variable domain (VH) are substituted for each other; and The first antigen is human A-beta protein and the second antigen is human transferrin receptor.

[0100] Antibody 0015 is also an embodiment of the present invention, and is composed of four polypeptides having the amino acid sequences of SEQ ID NOs:01 to 03 and SEQ ID NO:10.

[0101] Antibody 0015 is a bispecific antibody comprising: a) a full-length antibody comprising two pairs of full-length antibody light chains and full-length antibody heavy chains, wherein the binding site formed by each pair of full-length heavy chains and full-length light chains specifically binds to a first antigen; and b) one additional Fab fragment, in which the binding site of the additional Fab fragment specifically binds to a second antigen, is fused to the C-terminus of one heavy chain of the full-length antibody; each of the full-length antibody light chains comprises in the constant light domain (CL) the amino acid residue arginine at position 123 (instead of the wild-type glutamic acid residue; E123R mutation) and the amino acid residue lysine at position 124 (instead of the wild-type glutamine residue; Q124K mutation) (numbering according to Kabat); each of the full-length antibody heavy chains comprises in the first constant heavy chain domain (CH1) a glutamic acid residue at position 147 (instead of the wild-type lysine residue; K147E mutation) and a glutamic acid residue at position 213 (instead of the wild-type lysine amino acid residue; K213E mutation) (numbering according to the Kabat EU index); An additional Fab fragment that specifically binds to a second antigen comprises a domain crossover such that the constant light domain (CL) and the constant heavy domain 1 (CH1) are replaced by each other; and The first antigen is human A-beta protein and the second antigen is human transferrin receptor.

[0102] Antibody 0020 is also an embodiment of the present invention, and is composed of three polypeptides having the amino acid sequences of SEQ ID NOs:11-13.

[0103] Antibody 0020 is a bispecific antibody comprising: a) a full-length antibody comprising two pairs of full-length antibody light chains and full-length antibody heavy chains, wherein the binding site formed by each pair of full-length heavy chains and full-length light chains specifically binds to a first antigen; and b) one additional Fab fragment, in which the binding site of the additional Fab fragment specifically binds to a second antigen, is fused to the C-terminus of one heavy chain of the full-length antibody; each of the full-length antibody light chains comprises in the constant light domain (CL) the amino acid residue arginine at position 123 (instead of the wild-type glutamic acid residue; E123R mutation) and the amino acid residue lysine at position 124 (instead of the wild-type glutamine residue; Q124K mutation) (numbering according to Kabat); each of the full-length antibody heavy chains comprises in the first constant heavy chain domain (CH1) a glutamic acid residue at position 147 (instead of the wild-type lysine residue; K147E mutation) and a glutamic acid residue at position 213 (instead of the wild-type lysine amino acid residue; K213E mutation) (numbering according to the Kabat EU index); the additional Fab fragment that specifically binds to the second antigen is a single-chain Fab fragment, and The first antigen is human A-beta protein and the second antigen is human transferrin receptor.

[0104] Antibody 0024 is also an embodiment of the present invention, and is composed of four polypeptides having the amino acid sequences of SEQ ID NOs:14-17.

[0105] Antibody 0024 is a bispecific antibody comprising: a) a full-length antibody comprising two pairs of full-length antibody light chains and full-length antibody heavy chains, wherein the binding site formed by each pair of full-length heavy chains and full-length light chains specifically binds to a first antigen; and b) one additional Fab fragment, in which the binding site of the additional Fab fragment specifically binds to a second antigen, is fused to the C-terminus of one heavy chain of the full-length antibody; An additional Fab fragment that specifically binds to a second antigen comprises a domain crossover such that the constant light domain (CL) and the constant heavy domain 1 (CH1) are replaced by each other; and The first antigen is human A-beta protein and the second antigen is human transferrin receptor.

[0106] Different allocations / combinations of each polypeptide in different expression plasmids and different ratios of the resulting plasmids have been used for the recombinant production of bispecific antibodies. The results are presented in the table below. [Table 1]

[0107] The bispecific antibodies have been produced on a small scale and the distribution of by-products has been analyzed after a first purification step using Protein A affinity chromatography and after a second purification step using preparative size-exclusion chromatography. The results are presented in the table below. [Table 2] [Table 3] [Table 4]

[0108] The anti-A-beta binding site contains an additional glycosylation site. Glycosylation was therefore determined. The results are presented in the table below. [Table 5]

[0109] Percentage of non-glycosylated Fab in 3 liter fermentations after ProtA purification [Table 6]

[0110] Percentage of non-glycosylated Fab in 3 l fermentations after ProtA + SEC purification [Table 7]

[0111] The stability of the bispecific antibodies was tested by incubation in buffer at specific pH values ​​for 14 days, and the results are presented in the table below. [Table 8]

[0112] The aggregation temperatures for antibodies 0015 and 0024 were determined to be approximately 53-55°C, and for antibody 0012, approximately 54-56°C.

[0113] The off-rates (kd in [1 / Ms]) for binding to the human transferrin receptor as determined by BIAcore were similar at 25°C, 37°C, and 40°C for antibody 0015 and antibody 0024, and for the parent anti-human transferrin receptor antibody: 1.86E-02 to 1.97E-02, 198E-2 to 2.03E-2, and 1.44E-02, respectively.

[0114] The A-beta specific effector function of all antibodies was comparable to the parent monospecific anti-A-beta antibody in the U937 cell assay. The data are presented in the table below. [Table 9]

[0115] None of the bispecific antibodies demonstrated neutrophil activation in vitro.

[0116] Overall antibody 0015 exhibits suitable properties and is therefore a preferred embodiment of the present invention. Furthermore, this antibody has improved properties, notably an improved by-product profile.

[0117] In one aspect, provided herein is a bispecific antibody comprising: a) a full-length antibody comprising two pairs of full-length antibody light chains and full-length antibody heavy chains, wherein the binding site formed by each pair of full-length heavy chains and full-length light chains specifically binds to a first antigen; and b) one additional Fab fragment, in which the binding site of the additional Fab fragment specifically binds to a second antigen, is fused to the C-terminus of one heavy chain of the full-length antibody; each of the full-length antibody light chains comprises in the constant light domain (CL) the amino acid residue arginine at position 123 (instead of the wild-type glutamic acid residue; E123R mutation) and the amino acid residue lysine at position 124 (instead of the wild-type glutamine residue; Q124K mutation) (numbering according to Kabat); each of the full-length antibody heavy chains comprises in the first constant heavy chain domain (CH1) a glutamic acid residue at position 147 (instead of the wild-type lysine residue; K147E mutation) and a glutamic acid residue at position 213 (instead of the wild-type lysine amino acid residue; K213E mutation) (numbering according to the Kabat EU index); An additional Fab fragment that specifically binds to a second antigen comprises a domain crossover such that the constant light domain (CL) and the constant heavy domain 1 (CH1) are replaced by each other; and The first antigen is human A-beta protein and the second antigen is human transferrin receptor.

[0118] Another embodiment reported herein is a bispecific antibody comprising: a) a full-length antibody comprising two pairs of full-length antibody light chains and full-length antibody heavy chains, wherein the binding site formed by each pair of full-length heavy chains and full-length light chains specifically binds to a first antigen; and b) one additional Fab fragment, in which the binding site of the additional Fab fragment specifically binds to a second antigen, is fused to the C-terminus of one heavy chain of the full-length antibody; each of the full-length antibody light chains comprises in the constant light domain (CL) the amino acid residue arginine at position 123 (instead of the wild-type glutamic acid residue; E123R mutation) and the amino acid residue lysine at position 124 (instead of the wild-type glutamine residue; Q124K mutation) (numbering according to Kabat); each of the full-length antibody heavy chains comprises in the first constant heavy chain domain (CH1) a glutamic acid residue at position 147 (instead of the wild-type lysine residue; K147E mutation) and a glutamic acid residue at position 213 (instead of the wild-type lysine amino acid residue; K213E mutation) (numbering according to the Kabat EU index); an additional Fab fragment that specifically binds to a second antigen, comprising a domain crossover such that the constant light domain (CL) and the constant heavy domain 1 (CH1) are substituted for each other; the first antigen is human A-beta protein and the second antigen is human transferrin receptor; the human A-beta binding site comprises a heavy chain variable domain (VH) having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity to the amino acid sequence of SEQ ID NO: 18 and a light chain variable domain (VL) having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity to the amino acid sequence of SEQ ID NO: 19; and The human transferrin receptor binding site comprises a heavy chain variable domain (VH) having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the amino acid sequence of SEQ ID NO:20 and a light chain variable domain (VL) having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the amino acid sequence of SEQ ID NO:21.

[0119] In certain embodiments, a VH sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity contains substitutions (e.g., conservative substitutions), insertions, or deletions compared to a reference sequence, but a binding site comprising the sequence retains the ability to bind to its antigen. In certain embodiments, a total of 1-10 amino acids are substituted, inserted, and / or deleted in SEQ ID NO: 18 or 20. In certain embodiments, the substitutions, insertions, or deletions occur in a region outside the HVR (i.e., in the FR).

[0120] In certain embodiments, a VL sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity contains substitutions (e.g., conservative substitutions), insertions, or deletions compared to a reference sequence, but a binding site comprising the sequence retains the ability to bind to its antigen. In certain embodiments, a total of 1-10 amino acids are substituted, inserted, and / or deleted in SEQ ID NO: 19 or 21. In certain embodiments, the substitutions, insertions, or deletions occur in a region outside the HVR (i.e., in the FR).

[0121] In one embodiment, the human A-beta binding site comprises the VH sequence of SEQ ID NO: 18 (including post-translational modifications of that sequence) and the VL sequence of SEQ ID NO: 19 (including post-translational modifications of that sequence).

[0122] In one embodiment, the human transferrin receptor binding site comprises the VH sequence of SEQ ID NO:20 (including post-translational modifications of that sequence) and the VL sequence of SEQ ID NO:21 (including post-translational modifications of that sequence).

[0123] In one embodiment, the bispecific antibody comprises: i) a light chain having 70 to 100%, at least 70%, at least 80%, at least 90%, or 95% or more sequence identity to SEQ ID NO: 01; ii) a heavy chain having 70 to 100%, at least 70%, at least 80%, at least 90%, or 95% or more sequence identity to SEQ ID NO: 02; iii) a light chain having 70-100%, at least 70%, at least 80%, at least 90%, or 95% or more sequence identity to SEQ ID NO:03; and iv) a heavy chain Fab fragment having 70 to 100%, at least 70%, at least 80%, at least 90%, or 95% or more sequence identity to SEQ ID NO:04; where SEQ ID NO: 01 is the amino acid sequence [ka] having SEQ ID NO: 02 is the amino acid sequence [ka] having SEQ ID NO: 03 is the amino acid sequence [ka] and SEQ ID NO: 04 is the amino acid sequence [ka] has.

[0124] Another embodiment reported herein is a bispecific antibody comprising: a) a full-length antibody comprising two pairs of full-length antibody light chains and full-length antibody heavy chains, wherein the binding site formed by each pair of full-length heavy chains and full-length light chains specifically binds to a first antigen; and b) one additional Fab fragment, in which the binding site of the additional Fab fragment specifically binds to a second antigen, is fused to the C-terminus of one heavy chain of the full-length antibody; each of the full-length antibody light chains comprises in the constant light domain (CL) the amino acid residue arginine at position 123 (instead of the wild-type glutamic acid residue; E123R mutation) and the amino acid residue lysine at position 124 (instead of the wild-type glutamine residue; Q124K mutation) (numbering according to Kabat); each of the full-length antibody heavy chains comprises in the first constant heavy chain domain (CH1) a glutamic acid residue at position 147 (instead of the wild-type lysine residue; K147E mutation) and a glutamic acid residue at position 213 (instead of the wild-type lysine amino acid residue; K213E mutation) (numbering according to the Kabat EU index); an additional Fab fragment that specifically binds to a second antigen, comprising a domain crossover such that the constant light domain (CL) and the constant heavy domain 1 (CH1) are substituted for each other; the first antigen is human A-beta protein and the second antigen is human transferrin receptor; The human A-beta binding site comprises a heavy chain variable domain (VH) having the amino acid sequence of SEQ ID NO: 18 and a light chain variable domain (VL) having the amino acid sequence of SEQ ID NO: 19; and The human transferrin receptor binding site comprises a heavy chain variable domain (VH) having the amino acid sequence of SEQ ID NO:20 and a light chain variable domain (VL) having the amino acid sequence of SEQ ID NO:21.

[0125] Another embodiment reported herein is a bispecific antibody comprising: a) a full-length antibody comprising two pairs each of a full-length antibody light chain and a full-length antibody heavy chain, wherein a binding site formed by each of the pairs of full-length heavy chains specifically binds to a first antigen, and the full-length antibody comprises an Fc region formed by an Fc region polypeptide comprising the CH1, CH2, and CH3 domains of each of the two full-length heavy chains; and b) one additional Fab fragment, in which the binding site of the additional Fab fragment specifically binds to a second antigen, is fused to the C-terminus of one heavy chain of the full-length antibody; each of the full-length antibody light chains comprises in the constant light domain (CL) the amino acid residue arginine at position 123 (instead of the wild-type glutamic acid residue; E123R mutation) and the amino acid residue lysine at position 124 (instead of the wild-type glutamine residue; Q124K mutation) (numbering according to Kabat); each of the full-length antibody heavy chains comprises in the first constant heavy chain domain (CH1) a glutamic acid residue at position 147 (instead of the wild-type lysine residue; K147E mutation) and a glutamic acid residue at position 213 (instead of the wild-type lysine amino acid residue; K213E mutation) (numbering according to the Kabat EU index); an additional Fab fragment that specifically binds to a second antigen, comprising a domain crossover such that the constant light domain (CL) and the constant heavy domain 1 (CH1) are substituted for each other; the first antigen is human A-beta protein and the second antigen is human transferrin receptor; the human A-beta binding site comprises a heavy chain variable domain (VH) having the amino acid sequence of SEQ ID NO: 18 and a light chain variable domain (VL) having the amino acid sequence of SEQ ID NO: 19; the human transferrin receptor binding site comprises a heavy chain variable domain (VH) having the amino acid sequence of SEQ ID NO: 20 and a light chain variable domain (VL) having the amino acid sequence of SEQ ID NO: 21; wherein the Fc region polypeptide is: a) human subclass IgG1; b) human subclass IgG4; c) human subclass IgG1 with the mutations L234A, L235A, and P329G; d) human subclass IgG4 with the mutations S228P, L235E, and P329G; e) human subclass IgG1 with the mutations L234A, L235A, and P329G in both Fc region polypeptides, and the mutations T366W and S354C in one Fc region polypeptide, and the mutations T366S, L368A, Y407V, and Y349C in each of the other Fc region polypeptides; f) human subclass IgG4 with the mutations S228P and P329G in both Fc region polypeptides, and the mutations T366W and S354C in one Fc region polypeptide, and the mutations T366S, L368A, Y407V, and Y349C in each of the other Fc region polypeptides; g) human subclass IgG1 with the mutations L234A, L235A, P329G, I253A, H310A, and H435A in both Fc region polypeptides, and the mutations T366W and S354C in one Fc region polypeptide, and the mutations T366S, L368A, Y407V, and Y349C in the other respective Fc region polypeptide; h) human subclass IgG1 with the mutations L234A, L235A, P329G, M252Y, S254T, and T256E in both Fc region polypeptides, and the mutations T366W and S354C in one Fc region polypeptide, and the mutations T366S, L368A, Y407V, and Y349C in the other respective Fc region polypeptide, or A full-length antibody of human subclass IgG1 with the mutations i) L234A, L235A, P329G, H310A, H433A, and Y436A in both heavy chains, and the mutations i) T366W, and ii) S354C or Y349C in one heavy chain, and the mutations i) T366S, L368A, and Y407V, and ii) Y349C or S354C in each other heavy chain.

[0126] In further aspects, the bispecific anti-human A-beta / human transferrin receptor antibodies according to any of the above embodiments may incorporate any of the features, either alone or in combination, as described in Sections 1-3 below:

[0127] 1. Chimeric and humanized antibodies In certain embodiments, the antibody provided herein is a chimeric antibody. Certain chimeric antibodies are described, for example, in US 4,816,567; and Morrison, Slet al., Proc. Natl. Acad. Sci. USA 81 (1984) 6851-6855. In one example, the chimeric antibody comprises a non-human variable region (e.g., a variable region derived from a mouse, rat, hamster, rabbit, or a non-human primate, such as a monkey) and a human constant region. In a further example, the chimeric antibody is a "class-switched" antibody that has changed class or subclass from that of the parent antibody. The chimeric antibody includes an antigen-binding fragment thereof.

[0128] In certain embodiments, a chimeric antibody is a humanized antibody. Typically, a non-human antibody is humanized to reduce immunogenicity in humans while retaining the specificity and affinity of the parent non-human antibody. Generally, a humanized antibody comprises one or more variable domains in which the HVRs, e.g., CDRs (or portions thereof), are derived from a non-human antibody and the FRs (or portions thereof) are derived from a human antibody sequence. A humanized antibody will optionally also comprise at least a portion of a human constant region. In some embodiments, some FR residues in a humanized antibody are replaced with corresponding residues from the non-human antibody (e.g., the antibody from which the HVR residues are derived), e.g., to restore or improve antibody specificity or affinity.

[0129] Humanized antibodies and methods for making them are reviewed, for example, in Almagro, JC and Fransson, J., Front. Biosci. 13 (2008) 1619-1633, and are described, for example, in Riechmann, I., et al., Nature 332 (1988) 323-329; Queen, C., et al., Proc. Natl. Acad. Sci. USA 86 (1989) 10029-10033; US 5,821,337, US 7,527,791, US 6,982,321, and US 7,087,409; Kashmiri, SV, et al., Methods 36 (2005) 25-34 (describing specificity determining region (SDR) grafting); Padlan, EA, Mol. Immunol. 28 (2006) 101-102 (described above). (1991) 489-498 (describing "resurfacing"); Dall'Acqua, WF et al., Methods 36 (2005) 43-60 (describing "FR shuffling"); and Osbourn, J. et al., Methods 36 (2005) 61-68 and Klimka, A. et al., Br. J. Cancer 83 (2000) 252-260 (describing a "guided selection" approach to FR shuffling).

[0130] Human framework regions that may be used for humanization include framework regions selected using the "best-fit" method (see, e.g., Sims, MJ, et al., J. Immunol. 151 (1993) 2296-2308); framework regions derived from consensus sequences of human antibodies of a particular subgroup of light or heavy chain variable regions (see, e.g., Carter, P., et al., Proc. Natl. Acad. Sci. USA 89 (1992) 4285-4289; and Presta, LG, et al., J. Immunol. 151 (1993) 2623-2632); human mature (somatically mutated) framework regions or human germline framework regions (see, e.g., Almagro, JC and Fransson, J., Front. Biosci. 13 (2008) 1619-1633); and framework regions derived from screening of FR libraries (see, e.g., Baca, M. et al., J. Biol. Chem. 272 ​​(1997) 10678-10684 and Rosok, MJ et al., J. Biol. Chem. 271 (1996) 22611-22618).

[0131] 2. Human antibodies In certain embodiments, the antibody provided herein is a human antibody. Human antibodies can be produced using various techniques known in the art. Human antibodies are generally described in van Dijk, MA and van de Winkel, JG, Curr. Opin. Pharmacol. 5 (2001) 368-374 and Lonberg, N., Curr. Opin. Immunol. 20 (2008) 450-459.

[0132] Human antibodies can be prepared by administering immunogens to transgenic animals that have been engineered to produce intact human antibodies or intact antibodies with human variable regions in response to antigenic challenge. Such animals typically contain all or part of the human immunoglobulin loci, which replace endogenous immunoglobulin loci or are present extrachromosomally or randomly integrated into the animal's chromosomes. In such transgenic mice, the endogenous immunoglobulin loci are generally inactivated. For a review of methods for obtaining human antibodies from transgenic animals, see Lonberg, N., Nat. Biotech. 23 (2005) 1117-1125. See also, e.g., US 6,075,181 and US 6,150,584, describing XENOMOUSE™ technology; US 5,770,429, describing HUMAB® technology; US 7,041,870, describing KM MOUSE® technology, and US 2007 / 0061900, describing VELOCIMOUSE® technology. The human variable regions from intact antibodies produced by such animals may be further modified, for example, by combining with a different human constant region.

[0133] Human antibodies can also be made by hybridoma-based methods. Human myeloma cell lines and mouse-human heteromyeloma cell lines for the production of human monoclonal antibodies have been described (see, e.g., Kozbor, DJ, Immunol. 133 (1984) 3001-3005; Brodeur, BR, et al., Monoclonal Antibody Production Techniques and Applications, Marcel Dekker, Inc., New York (1987), pp. 51-63; and Boerner, P., et al., J. Immunol. 147 (1991) 86-95). Human antibodies generated via human B-cell hybridoma technology have also been described in Li, J. et al., Proc. Natl. Acad. Sci. USA 103 (2006) 3557-3562. Additional methods include, for example, those described in US 7,189,826 (describing the production of monoclonal human IgM antibodies from hybridoma cell lines) and Ni, J., Xiandai Mianyixue 26 (2006) 265-268 (describing human-human hybridomas). Human hybridoma technology (trioma technology) is also described in Vollmers, HP and Brandlein, S., Histology and Histopathology 20 (2005) 927-937 and Vollmers, HP and Brandlein, S., Methods and Findings in Experimental and Clinical Pharmacology 27 (2005) 185-191.

[0134] Human antibodies may also be generated by isolating Fv clone variable domain sequences selected from a human-derived phage display library. Such variable domain sequences may then be combined with the desired human constant domains. Techniques for selecting human antibodies from antibody libraries are described below.

[0135] 3. Antibody variants In certain embodiments, amino acid sequence variants of the antibodies provided herein are contemplated. For example, it may be desired to improve the binding affinity and / or other biological properties of the antibody. Amino acid sequence variants of the antibodies may be prepared by introducing appropriate modifications into the nucleotide sequence encoding the antibody or by peptide synthesis. Such modifications include, for example, deletions from, and / or insertions into, and / or substitutions of residues within the amino acid sequence of the antibody. Any combination of deletions, insertions, and substitutions can be made to arrive at the final construct, provided that the final construct possesses the desired characteristics (e.g., antigen binding).

[0136] a) Substitution, insertion, and deletion variants In certain embodiments, antibody variants with one or more amino acid substitutions are provided. Sites of interest for substitutional mutagenesis include HVRs and FRs. Conservative substitutions are shown in the table below under the heading of "preferred substitutions." More substantial changes are provided in Table 1 under the heading of "exemplary substitutions" and are further described below with reference to amino acid side chain classes. Amino acid substitutions may be introduced into the antibody of interest and the products screened for a desired activity (e.g., retained / improved antigen binding, reduced immunogenicity, or improved ADCC or CDC). [Table 10]

[0137] Amino acids can be grouped according to common side chain properties: (1) Hydrophobic: Norleucine, Met, Ala, Val, Leu, Ile; (2) Neutral hydrophilic: Cys, Ser, Thr, Asn, Gln; (3) Acidic: Asp, Glu; (4) Basic: His, Lys, Arg; (5) Residues that affect chain orientation: Gly, Pro; (6) Aromatic: Trp, Tyr, Phe.

[0138] Conservative substitutions may involve exchanging a member of one of these classes for another class.

[0139] One type of substitutional variant involves substituting one or more hypervariable region residues of a parent antibody (e.g., a humanized or human antibody). Typically, the resulting variants selected for further testing have an alteration (e.g., improvement) in a particular biological property (e.g., increased affinity, reduced immunogenicity) compared to the parent antibody and / or substantially retain a particular biological property of the parent antibody. An exemplary substitutional variant is an affinity matured antibody, which may be conveniently generated, for example, using phage display-based affinity maturation techniques (such as those described herein). Briefly, one or more HVR residues are mutated and the variant antibodies are displayed on phage and screened for a particular biological activity (e.g., binding affinity).

[0140] Changes (e.g., substitutions) may be made in the HVRs, for example, to improve the affinity of the antibody. Such changes may be made in HVR "hot spots", i.e., residues encoded by codons that undergo frequent mutation during the somatic maturation process (see, e.g., Chowdhury, PS, Methods Mol. Biol. 207 (2008) 179-196), and / or in residues that contact the antigen, and the resulting variants VH or VL are tested for binding affinity. Affinity maturation by construction and reselection from secondary libraries is described, for example, in Hoogenboom, HR et al. Methods in Molecular Biology 178 (2002) 1-37. In some embodiments of affinity maturation, diversity is introduced into the variable genes chosen for maturation by any of a variety of methods (e.g., error-prone PCR, chain shuffling, or oligonucleotide-directed mutagenesis). A secondary library is then generated. The library is then screened to identify any antibody variants with the desired affinity. Another method for introducing diversity involves an HVR-directed approach, in which several HVR residues (e.g., 4-6 residues at a time) are randomized. HVR residues involved in antigen binding can be specifically identified, for example, using alanine scanning mutagenesis or modeling. CDR-H3 and CDR-L3 in particular are often targeted.

[0141] In certain embodiments, substitutions, insertions, or deletions may be made within one or more HVRs, so long as such changes do not substantially reduce the ability of the antibody to bind to the antigen. For example, conservative changes (e.g., conservative substitutions as provided herein) that do not substantially reduce binding affinity may be made in the HVRs. Such changes may, for example, be outside of antigen contact residues in the HVRs. In certain embodiments of the variant VH and VL sequences provided above, either of the respective HVRs is unchanged or contains less than one, two, or three amino acid substitutions.

[0142] A useful method for identifying residues or regions of an antibody that can be targeted for mutagenesis is called "alanine scanning mutagenesis" and is as described by Cunningham and Wells in Science, 244: 1081-1085 (1989). In this method, a residue or group of target residues (e.g., charged residues such as arg, asp, his, lys, and glu) is identified and substituted with neutral or negatively charged amino acids (e.g., alanine or polyalanine) to determine whether the interaction of the antibody with the antigen is affected. Further substitutions may be introduced at the amino acid positions to demonstrate functional sensitivity to the initial substitution. Alternatively, or in addition, a crystal structure of an antigen-antibody complex to identify contact points between the antibody and antigen. Such contact and adjacent residues may be targeted or eliminated as candidates for substitution. The variants may be screened to determine whether they contain the desired properties.

[0143] Amino acid sequence insertions include amino- and / or carboxy-terminal fusions ranging in length from one residue to polypeptides containing 100 or more residues, as well as intrasequence insertions of single or multiple amino acid residues. An example of a terminal insertion includes an antibody with an N-terminal methionyl residue. Other insertional variants of the antibody molecule include the fusion to the N- or C-terminus of the antibody to an enzyme (e.g., for ADEPT) or a polypeptide which increases the serum half-life of the antibody.

[0144] b) Glycosylation variants In certain embodiments, the antibodies provided herein are altered to increase or decrease the extent to which the antibody is glycosylated. Addition or deletion of glycosylation sites to an antibody may conveniently be accomplished by altering the amino acid sequence such that one or more glycosylation sites are created or removed.

[0145] If the antibody comprises an Fc region, the carbohydrate attached thereto may be varied. Natural antibodies produced by mammalian cells typically contain branched, biantennary oligosaccharides that are commonly attached by N-linkage to Asn297 in the CH2 domain of the Fc region. See, e.g., Wright, A. and Morrison, SL, TIBTECH 15 (1997) 26-32. The oligosaccharides may contain a variety of carbohydrates, such as mannose, N-acetylglucosamine (GlcNAc), galactose, and sialic acid, as well as fucose attached to the GlcNAc in the "stem" of the biantennary oligosaccharide structure. In some embodiments, modifications of the oligosaccharides in the antibodies reported herein may be made to generate antibody variants with specific improved properties.

[0146] In one embodiment, antibody variants are provided that have a carbohydrate structure that lacks fucose attached (directly or indirectly) to the Fc region. For example, the amount of fucose in such antibodies can be between 1% and 80%, between 1% and 65%, between 5% and 65%, or between 20% and 40%. The amount of fucose is determined by calculating the average amount of fucose in the glycan at Asn297 compared to the sum of all carbohydrate structures (e.g. complex, hybrid and high mannose structures) attached to Asn 297, as measured, for example, by MALDI-TOF mass spectrometry as described in WO2008 / 077546. Asn297 refers to an asparagine residue located at about position 297 (EU numbering of Fc region residues) in the Fc region. However, Asn297 can also be located about ±3 amino acids upstream or downstream of position 297, i.e., between positions 294 and 300, due to minor sequence variations in antibodies. Such fucosylation variants may have improved ADCC function. See, e.g., US 2003 / 0157108; US 2004 / 0093621. Examples of publications relating to "defucosylated" or "fucose-deficient" antibody variants include US 2003 / 0157108; WO 2000 / 61739; WO 2001 / 29246; US 2003 / 0115614; US 2002 / 0164328; US 2004 / 0093621; US ​​2004 / 0132140; US 2004 / 0110704; US 2004 / 0110282; US 2004 / 0109865; WO 2003 / 085119; WO 2003 / 084570; WO 2005 / 035586; WO 2005 / 035778; WO 2005 / 053742; WO 2002 / 031140; Okazaki, A. et al., J. Mol. Biol. 336 (2004) 1239-1249; Yamane-Ohnuki, N. et al., Biotech. Bioeng. 87 (2004) 614-622.Examples of cell lines capable of producing defucosylated antibodies include Lec13 CHO cells, which are deficient in protein fucosylation (Ripka, J., et al., Arch. Biochem. Biophys. 249 (1986) 533-545; US 2003 / 0157108; and WO 2004 / 056312, especially Example 11), and knockout cell lines, such as alpha-1,6-fucosyltransferase gene, FUT8 knockout CHO cells (see, e.g., Yamane-Ohnuki, N., et al., Biotech. Bioeng. 87 (2004) 614-622; Kanda, Y.et al., Biotechnol. Bioeng. 94 (2006) 680-688; and WO2003 / 085107).

[0147] Further provided are antibody variants with bisected oligosaccharides, for example, in which the biantennary oligosaccharide attached to the Fc region of the antibody is bisected by GlcNAc. Such antibody variants may have reduced fucosylation and / or improved ADCC function. Examples of such antibody variants are described, for example, in WO 2003 / 011878; US 6,602,684; and US 2005 / 0123546. Also provided are antibody variants with at least one galactose residue in the oligosaccharide attached to the Fc region. Such antibody variants may have improved CDC function. Such antibody variants are described, for example, in WO 1997 / 30087; WO 1998 / 58964; and WO 1999 / 22764.

[0148] c) Fc domain variants In certain embodiments, one or more additional amino acid modifications may be introduced into the Fc region of an antibody provided herein, thereby generating an Fc region variant. The Fc region variant may comprise a human Fc region sequence (e.g., a human IgG1, IgG2, IgG3, or IgG4 Fc region) that contains an amino acid modification (e.g., a substitution) at one or more amino acid positions.

[0149] Certain embodiments contemplate antibody variants with some but not all effector functions that make them desirable candidates for applications where in vivo antibody half-life is important, but certain effector functions (such as complement and ADCC) are unnecessary or detrimental. In vitro and / or in vivo cytotoxicity assays can be performed to confirm reduced / depleted CDC and / or ADCC activity. For example, Fc receptor (FcR) binding assays can be performed to ensure that the antibody lacks FcγR binding (and thus likely has no ADCC activity) but retains FcRn binding ability. NK cells, the primary cells for mediating ADCC, express only FcγRIII, whereas monocytes express FcγRI, FcγRII, and FcγRIII. FcR expression on hematopoietic cells is summarized in Table 3 on page 464 of Ravetch, JV and Kinet, JP, Annu. Rev. Immunol. 9 (1991) 457-492. Non-limiting examples of in vitro assays to assess ADCC activity of a molecule of interest are described in US 5,500,362 (see, e.g., Hellstrom, I. et al., Proc. Natl. Acad. Sci. USA 83 (1986) 7059-7063; and Hellstrom, I. et al., Proc. Natl. Acad. Sci. USA 82 (1985) 1499-1502); US 5,821,337 (see, Bruggemann, M. et al., J. Exp. Med. 166 (1987) 1351-1361). Alternatively, non-radioactive assay methods may be used (see, e.g., ACTI™ Non-Radioactive Cytotoxicity Assay for Flow Cytometry (CellTechnology, Inc., Mountain View, Calif.; and CytoTox 96® Non-Radioactive Cytotoxicity Assay (Promega, Madison, Wis.)). Useful effector cells for such assays include peripheral blood mononuclear cells (PBMC) and natural killer (NK) cells.Alternatively, or additionally, ADCC activity of the molecule of interest may be assessed in vivo (e.g., in an animal model such as that disclosed in Clynes, R. et al., Proc. Natl. Acad. Sci. USA 95 (1998) 652-656). C1q binding assays may also be performed to confirm that the antibody is unable to bind C1q and thus lacks CDC activity. See, e.g., C1q and C3c binding ELISAs in WO2006 / 029879 and WO2005 / 100402. To assess complement activation, a CDC assay may be performed (see, e.g., Gazzano-Santoro, H. et al., J. Immunol. Methods 202 (1996) 163-171; Cragg, MS et al., Blood 101 (2003) 1045-1052; and Cragg, MS and MJ Glennie, Blood 103 (2004) 2738-2743). FcRn binding and in vivo clearance / half-life determinations can also be performed using methods known in the art (see, e.g., Petkova, SB et al., Int. Immunol. 18 (2006: 1759-1769).

[0150] Antibodies with reduced effector function include antibodies with one or more substitutions at Fc region residues 238, 265, 269, 270, 297, 327, and 329 (US 6,737,056). Such Fc variants include Fc variants with substitutions at two or more of amino acid positions 265, 269, 270, 297, and 327, including the so-called "DANA" Fc variant with substitutions of residues 265 and 297 to alanine (US 7,332,581).

[0151] Certain antibody variants with improved or diminished binding to FcRs have been described (see, e.g., US 6,737,056; WO 2004 / 056312, and Shields, RL et al., J. Biol. Chem. 276 (2001) 6591-6604).

[0152] In certain embodiments, the antibody variant comprises an Fc region with one or more amino acid substitutions that improve ADCC, e.g., substitutions at positions 298, 333, and / or 334 (EU numbering of residues) of the Fc region.

[0153] In some embodiments, changes are made in the Fc region that result in altered (i.e., improved or diminished) C1q binding and / or complement dependent cytotoxicity (CDC), e.g., as described in US 6,194,551, WO 99 / 51642, and Idusogie, EE et al., J. Immunol. 164 (2000) 4178-4184.

[0154] Antibodies with increased half-life and improved binding to the neonatal Fc receptor (FcRn), responsible for the transfer of maternal IgG to the fetus (Guyer, RL et al., J. Immunol. 117 (1976) 587-593, and Kim, JK et al., J. Immunol. 24 (1994) 2429-2434), have been described in US 2005 / 0014934. These antibodies comprise an Fc region with one or more substitutions which improve binding of the Fc region to FcRn. Such Fc variants include those with substitutions at one or more of Fc region residues 238, 256, 265, 272, 286, 303, 305, 307, 311, 312, 317, 340, 356, 360, 362, 376, 378, 380, 382, ​​413, 424, or 434, e.g., substitution of Fc region residue 434 (US 7,371,826).

[0155] See also Duncan, AR and Winter, G., Nature 322 (1988) 738-740; US 5,648,260; US 5,624,821; and WO 94 / 29351 for other examples of Fc region variants.

[0156] d) Cysteine ​​Engineered Antibody Variants In certain embodiments, it may be desirable to generate cysteine ​​engineered antibodies (e.g., "thioMAbs") in which one or more residues of an antibody are replaced with a cysteine ​​residue. In certain embodiments, the replaced residues occur at accessible sites of the antibody. By replacing those residues with cysteine, reactive thiol groups are thereby positioned at accessible sites of the antibody, which may be used to conjugate the antibody to other moieties, such as drug moieties or linker-drug moieties, to generate immunoconjugates, as further described herein. In certain embodiments, any one or more of the following residues may be replaced with cysteine: V205 (Kabat numbering) of the light chain; A118 (EU numbering) of the heavy chain; and S400 (EU numbering) of the heavy chain Fc region. Cysteine ​​engineered antibodies may be generated, for example, as described in US 7,521,541.

[0157] e) Antibody derivatives In certain embodiments, the antibodies provided herein may be further modified to include additional non-proteinaceous components that are known in the art and readily available. Moieties suitable for derivatization of antibodies include, but are not limited to, water-soluble polymers. Non-limiting examples of water-soluble polymers include, but are not limited to, polyethylene glycol (PEG), ethylene glycol / propylene glycol copolymers, carboxymethylcellulose, dextran, polyvinyl alcohol, polyvinylpyrrolidone, poly-1,3-dioxolane, poly-1,3,6-trioxane, ethylene / maleic anhydride copolymers, polyamino acids (either homopolymers or random copolymers), and dextran or poly(n-vinylpyrrolidone) polyethylene glycol, propropylene glycol homopolymer, prolypropylene oxide / ethylene oxide copolymer, polyoxyethylated polyols (e.g., glycerol), polyvinyl alcohol, and mixtures thereof. Polyethylene glycol propionaldehyde may have advantages in manufacturing due to its stability in water. The polymers can be of any molecular weight, branched or unbranched. The number of polymers attached to the antibody can vary, but when more than one polymer is attached, they can be the same or different molecules. In general, the number and / or type of polymers used for derivatization can be determined based on considerations (including, but not limited to, the particular property or function of the antibody to be improved), whether or not the antibody derivative will be used in therapy under a defined condition, etc.

[0158] In another embodiment, a conjugate of an antibody and a non-proteinaceous moiety is provided that can be selectively heated by exposure to radiation. In one embodiment, the non-proteinaceous moiety is a carbon nanotube (Kam, NW et al., Proc. Natl. Acad. Sci. USA 102 (2005) 11600-11605). The radiation can be of any wavelength, including but not limited to wavelengths that do not harm normal cells but heat the non-proteinaceous moiety to a temperature where cells in proximity to the antibody-non-proteinaceous moiety are killed.

[0159] B. Recombinant Methods and Compositions The antibodies may be produced, for example, using recombinant methods and compositions described in US 4,816,567. In one embodiment, an isolated nucleic acid is provided that encodes a bispecific anti-human A-beta / human transferrin receptor antibody as described herein. Such a nucleic acid may encode an amino acid sequence comprising the VL and / or an amino acid sequence comprising the VH of the antibody (e.g., the light and / or heavy chains of the antibody). In a further embodiment, one or more vectors (e.g., expression vectors) comprising such a nucleic acid are provided. In a further embodiment, a host cell comprising such a nucleic acid is provided. In one such embodiment, the host cell comprises (e.g., is transformed with): (1) a vector comprising a nucleic acid encoding an amino acid sequence comprising the VL of the antibody and an amino acid sequence comprising the VH of the antibody, or (2) a first vector comprising a nucleic acid encoding an amino acid sequence comprising the VL of the antibody and a second vector comprising a nucleic acid encoding an amino acid sequence comprising the VH of the antibody. In one embodiment, the host cell is eukaryotic, for example, a Chinese hamster ovary (CHO) cell or a lymphoid cell (e.g., Y0, NS0, Sp20 cell). In one embodiment, there is provided a method of making a bispecific anti-human A-beta / human transferrin receptor antibody, the method comprising culturing a host cell comprising nucleic acid encoding the antibody as provided above under conditions suitable for expression of the antibody, and optionally recovering the antibody from the host cell (or host cell culture medium).

[0160] For recombinant production of bispecific anti-human A-beta / human transferrin receptor antibodies, nucleic acids encoding the antibodies (e.g., as described above) are isolated and inserted into one or more vectors for further cloning and / or expression in host cells. Such nucleic acids can be readily isolated and sequenced using conventional procedures (e.g., by using oligonucleotide probes capable of specifically binding to genes encoding the heavy and light chains of the antibody).

[0161] Suitable host cells for cloning or expressing antibody-encoding vectors include prokaryotic or eukaryotic cells as described herein. For example, antibodies can be produced in bacteria, particularly if glycosylation and Fc effector functions are not required. For expression of antibody fragments and polypeptides in bacteria, see, for example, US 5,648,237, US 5,789,199, and US 5,840,523 (see also Charlton, KA, In: Methods in Molecular Biology, Vol. 248, Lo, BKC (ed.), Humana Press, Totowa, NJ (2003), pp. 245-254, which describes the expression of antibody fragments in E. coli). After expression, the antibody may be isolated from the bacterial cell paste in a soluble fraction and can be further purified.

[0162] In addition to prokaryotes, eukaryotic microbes such as filamentous fungi or yeast are suitable cloning or expression hosts for antibody-encoding vectors, including fungal and yeast strains in which the glycosylation pathway has been "humanized," resulting in the production of antibodies with partially or fully human glycosylation patterns. See Gerngross, TU, Nat. Biotech. 22 (2004) 1409-1414; and Li, H. et al., Nat. Biotech. 24 (2006) 210-215.

[0163] Suitable host cells for the expression of glycosylated antibodies are also derived from multicellular organisms (invertebrates and vertebrates). Examples of invertebrate cells include plant cells and insect cells. Numerous baculovirus strains have been identified that can be used in conjunction with insect cells, particularly for transfection of Spodoptera frugiperda cells.

[0164] Plant cell cultures can also be used as hosts, see, e.g., US 5,959,177, US 6,040,498, US 6,420,548, US 7,125,978, and US 6,417,429 (describing the PLANTIBODIES™ technology for producing antibodies in transgenic plants).

[0165] Vertebrate cells may also be used as hosts. For example, mammalian cell lines that have been adapted to grow in suspension may be useful. Other examples of useful mammalian host cell lines are the SV40 transformed monkey kidney CV1 line (COS-7); human embryonic kidney lines (e.g., 293 or 293 cells described in Graham, FL, et al., J. Gen Virol. 36 (1977) 59-74); baby hamster kidney cells (BHK); mouse Sertoli cells (e.g., TM4 cells described in Mather, JP, Biol. Reprod. 23 (1980) 243-252); monkey kidney cells (CV1); African green monkey kidney cells (VERO-76); human cervical carcinoma cells (HELA); canine kidney cells (MDCK); buffalo rat liver cells (BRL 3A); human lung cells (W138); human hepatocytes (Hep G2); mouse mammary tumor (MMT 060562); TRI cells (e.g., Mather, JP, et al., Annals NY Acad. Sci. 383-384); (1982) 44-68); MRC5 cells; and FS4 cells. Other useful mammalian host cell lines include Chinese hamster ovary (CHO) cells (including DHFR-CHO cells) (Urlaub, G., et al., Proc. Natl. Acad. Sci. USA 77 (1980) 4216-4220); and myeloma cell lines (such as Y0, NS0, and SP2 / 0). For a review of specific mammalian host cell lines suitable for antibody production, see, for example, Yazaki, P. and Wu, AM, Methods in Molecular Biology, Vol. 248, Lo, BKC (ed.), Humana Press, Totowa, NJ (2004), pp. 255-268.

[0166] C. Methods and Compositions for Diagnosis and Detection In certain embodiments, any of the bispecific anti-human A-beta / human transferrin receptor antibodies provided herein are useful for detecting the presence of A-beta in a biological sample. As used herein, the term "detect" encompasses quantitative or qualitative detection. In certain embodiments, the biological sample comprises a cell or tissue.

[0167] In one embodiment, a bispecific anti-human A-beta / human transferrin receptor antibody is provided for use in a method of diagnosis or detection. In a further aspect, a method for detecting the presence of A-beta in a biological sample is provided. In a particular embodiment, the method comprises contacting a biological sample with a bispecific anti-human A-beta / human transferrin receptor antibody described herein under conditions permissive for binding of the bispecific anti-human A-beta / human transferrin receptor antibody to A-beta, and detecting whether a complex is formed between the bispecific anti-human A-beta / human transferrin receptor antibody and A-beta. Such a method can be an in vitro or in vivo method.

[0168] In certain embodiments, a labeled bispecific anti-human A-beta / human transferrin receptor antibody is provided. Labels include, but are not limited to, labels or moieties that are directly detected (e.g., fluorescent labels, chromophore labels, electron-dense labels, chemiluminescent labels, and radioactive labels) as well as moieties, such as enzymes or ligands, that are indirectly detected, for example, through an enzymatic reaction or molecular interaction. Exemplary labels include radioisotopes. 32 P, 14 C. 125 I, 3 H, and 131I, fluorophores such as rare earth chelates or fluorescein and its derivatives, rhodamine and its derivatives, dansyl, umbelliferone, luciferases (e.g., firefly luciferase and bacterial luciferase (US 4,737,456)), luciferin, 2,3-dihydrophthalazinediones, horseradish peroxidase (HRP), alkaline phosphatase, β-galactosidase, glucoamylase, lysozyme, saccharide oxidases (e.g., glucose oxidase, galactose oxidase, and glucose-6-phosphate dehydrogenase), heterocyclic oxidases such as uricase and xanthine oxidase in combination with an enzyme that uses hydrogen peroxide to oxidize a dye precursor (e.g., HRP, lactoperoxidase, or microperoxidase), biotin / avidin, spin labels, bacteriophage labels, stable free radicals, and the like.

[0169] D. Pharmaceutical Preparations Pharmaceutical formulations of the bispecific anti-human A-beta / human transferrin receptor antibodies described herein are prepared in the form of lyophilized formulations or aqueous solutions by mixing such antibodies having the desired degree of purity with one or more any pharma- ceutically acceptable carriers (Remington's Pharmaceutical Sciences, 16th edition, Osol, A. (ed.) (1980)). Pharmaceutically acceptable carriers are generally non-toxic to recipients at the dosages and concentrations employed and may contain any of the following: buffers, such as phosphates, citrates, and other organic acids; antioxidants, including ascorbic acid and methionine; preservatives, such as octadecyldimethylbenzylammonium chloride; hexamethonium chloride; benzalkonium chloride; benzethonium chloride; phenol, butyl or benzyl alcohol; alkyl parabens, such as methyl or propyl paraben; catechol; resorcinol; cyclohexanol; 3-pentanol; and m-cresol; low molecular weight (less than about 10 residues) polypeptides; proteins, such as Examples of suitable pharmacopoeitic carriers include, but are not limited to, serum albumin, gelatin, or immunoglobulins; hydrophilic polymers, such as poly(vinylpyrrolidone); amino acids, such as glycine, glutamine, asparagine, histidine, arginine, or lysine; monosaccharides, disaccharides, and other carbohydrates, including glucose, mannose, or dextrin; chelating agents, such as EDTA; sugars, such as sucrose, mannitol, trehalose, or sorbitol; salt-forming counterions, such as sodium; metal complexes, such as Zn-protein complexes; and / or non-ionic surfactants, such as polyethylene glycol (PEG). Exemplary pharmacopoeitic carriers, as used herein, further include interstitial drug dispersion agents, such as soluble neutral active hyaluronidase glycoproteins (sHASEGPs), such as human soluble PH-20 hyaluronidase glycoproteins, such as rhuPH20 (HYLENEX®, Baxter International, Inc.). Certain exemplary sHASEGPs and methods of use, including rhuPH20, are described in US 2005 / 0260186 and US 2006 / 0104968.In one embodiment, the sHASEGP is combined with one or more additional glycosaminoglycanases, such as, for example, chondroitinases.

[0170] Exemplary lyophilized antibody formulations are described in US 6,267,958. Aqueous antibody formulations include those described in US 6,171,586 and WO 2006 / 044908, the latter of which includes a histidine-acetate buffer.

[0171] The formulations herein may also contain more than one active ingredient as necessary for the particular indication being treated, preferably active ingredients with complementary activities that do not adversely affect each other. Such active ingredients are suitably present in combination in amounts that are effective for the purpose intended.

[0172] The active ingredient may be encapsulated in microcapsules prepared, for example, by coacervation techniques or by interfacial polymerization, for example, in colloidal drug delivery systems (e.g., liposomes, albumin microspheres, microemulsions, nanoparticles, and nanocapsules) or in macroemulsions, e.g., hydroxymethylcellulose or gelatin-microcapsules and poly-(methyl methacrylate) microcapsules, respectively. Such techniques are disclosed in Remington's Pharmaceutical Sciences, 16th edition, Osol, A. (ed.) (1980).

[0173] Sustained release preparations may be prepared. Suitable examples of sustained release preparations include semipermeable matrices of solid hydrophobic polymers containing the antibody, which matrices are in the form of shaped articles (e.g., films, or microcapsules). Examples of sustained release matrices include, but are not limited to, polyesters, hydrogels (e.g., poly(2-hydroxyethyl methacrylate) or poly(vinyl alcohol)), polylactides (US 3,773,919), copolymers of L-glutamic acid and gamma-ethyl-L-glutamic acid, non-degradable ethylene-vinyl acetate, degradable lactic acid-glycolic acid copolymers, such as LUPRON DEPOT™ (injectable microspheres composed of lactic acid-glycolic acid copolymer and leuprolide acetate), and poly-D-(-)-3-hydroxybutyric acid.

[0174] Formulations to be used for in vivo administration are generally sterile. Sterility may be readily accomplished, for example, by filtration through sterile filtration membranes. In one embodiment, the formulation is isotonic.

[0175] E. Treatment Methods and Compositions Any of the bispecific anti-human A-beta / human transferrin receptor antibodies provided herein may be used in therapeutic methods.

[0176] In one aspect, a bispecific anti-human A-beta / human transferrin receptor antibody is provided for use as a medicament. In a further aspect, a bispecific anti-human A-beta / human transferrin receptor antibody is provided for use in the prevention and / or treatment of a disease associated with amyloid formation and / or amyloid plaque formation. In a particular embodiment, a bispecific anti-human A-beta / human transferrin receptor antibody is provided for use in a method of treatment. In a particular embodiment, a bispecific anti-human A-beta / human transferrin receptor antibody is provided for use in a method of treating an individual having a disease associated with amyloid formation and / or amyloid plaque formation comprising administering to the individual an effective amount of a bispecific anti-human A-beta / human transferrin receptor antibody. In one such embodiment, the method further comprises administering to the individual an effective amount of at least one additional therapeutic agent as listed below or an anti-pTau antibody or an anti-alpha-synuclein antibody. In a further embodiment, a bispecific anti-human A-beta / human transferrin receptor antibody is provided herein for use in inhibiting plaque formation and / or degrading beta amyloid plaques. In certain embodiments, there is provided a bispecific anti-human A-beta / human transferrin receptor antibody for use in a method of inhibiting plaque formation and / or degrading beta-amyloid plaques in an individual comprising administering to the individual a bispecific anti-human A-beta / human transferrin receptor antibody to inhibit plaque formation and / or degrade beta-amyloid plaques. An "individual" according to any of the above embodiments is preferably a human.

[0177] In a further aspect, there is provided herein the use of a bispecific anti-human A-beta / human transferrin receptor antibody in the manufacture or preparation of a medicament. In one embodiment, the medicament is for the treatment of a disease associated with amyloid formation and / or amyloid plaque formation. In a further embodiment, the medicament is for use in a method of treating a disease associated with amyloid formation and / or amyloid plaque formation comprising administering an effective amount of the medicament to an individual having a disease associated with amyloid formation and / or amyloid plaque formation. In one such embodiment, the method further comprises administering to the individual an effective amount of at least one additional therapeutic agent as listed below or an anti-pTau antibody or an anti-alpha synuclein antibody. In a further embodiment, the medicament is for the inhibition of plaque formation and / or the degradation of beta amyloid plaques. In a further embodiment, the medicament is for use in a method of inhibiting plaque formation and / or the degradation of beta amyloid plaques in an individual comprising administering to the individual an effective amount of the medicament to inhibit plaque formation and / or the degradation of beta amyloid plaques. The "individual" according to any of the above embodiments may be a human.

[0178] In a further aspect, provided herein is a method for treating a disease associated with amyloidogenesis and / or amyloid plaque formation. In one embodiment, the method comprises administering to an individual having a disease associated with amyloidogenesis and / or amyloid plaque formation an effective amount of a bispecific anti-human A-beta / human transferrin receptor antibody. In one such embodiment, the method further comprises administering to the individual an effective amount of at least one additional therapeutic agent (e.g., as described below) or an anti-pTau antibody or an anti-alpha-synuclein antibody. An "individual" according to any of the above embodiments may be a human.

[0179] In a further aspect, provided herein is a method for inhibiting plaque formation and / or degrading beta-amyloid plaques in an individual. In one embodiment, the method comprises administering to the individual an effective amount of a bispecific anti-human A-beta / human transferrin receptor antibody to inhibit plaque formation and / or degrade beta-amyloid plaques. In one embodiment, the "individual" is a human.

[0180] In a further aspect, provided herein is a pharmaceutical formulation comprising any of the bispecific anti-human A-beta / human transferrin receptor antibodies provided herein, e.g., for use in any of the above methods of treatment. In one embodiment, the pharmaceutical formulation comprises any of the anti-human A-beta / human transferrin receptor antibodies provided herein and a pharma- ceutical acceptable carrier. In another embodiment, the pharmaceutical formulation comprises any of the bispecific anti-human A-beta / human transferrin receptor antibodies provided herein and at least one additional therapeutic agent, e.g., as described below, or an anti-pTau antibody or an anti-alpha-synuclein antibody.

[0181] The antibody of the present invention can be used alone or in combination with other agents in therapy.For example, the antibody reported herein may be co-administered with at least one additional therapeutic agent.In certain embodiments, the additional therapeutic agent is an effective therapeutic agent for treating the same or different neurological disorder as that treated with the bispecific antibody reported herein. Exemplary additional therapeutic agents include, but are not limited to, the various neurological drugs described above, cholinesterase inhibitors (e.g., donepezil, galantamine, lovastigmine, and tacrine), NMDA receptor antagonists (e.g., memantine), amyloid beta peptide aggregation inhibitors, antioxidants, gamma secretase modulators, nerve growth factor (NGF) mimetics or NGF gene therapy agents, PPARγ agonists, HMS-CoA reductase inhibitors (statins), ampakines, calcium channel blockers, GABA receptor antagonists, glycogen synthase kinase inhibitors, intravenous immunoglobulins, muscarinic receptor agonists, nicrothine receptor modulators, active or passive amyloid beta peptide immunization, phosphodiesterase inhibitors, serotonin receptor antagonists, and anti-amyloid beta peptide antibodies. In certain embodiments, at least one additional therapeutic agent is selected for its ability to alleviate one or more side effects of the neurological drug.

[0182] Combination treatment as described above includes combined administration (when two or more therapeutic agents are included in the same or separate formulations) and separate administration, in which case administration of the antibody as reported herein can precede, occur simultaneously and / or occur subsequent to administration of the additional therapeutic agent or agent. In one embodiment, administration of the bispecific anti-human A-beta / human transferrin receptor antibody and administration of the additional therapeutic agent occur within about one month of each other, or within about one, two, or three weeks, or within about one, two, three, four, five, or six days. The antibodies as reported herein can also be used in combination with other interventional therapies, such as, but not limited to, radiation therapy, behavioral therapy, or other therapies known in the art and appropriate for the neurological disorder being treated or prevented.

[0183] The antibodies (and any additional therapeutic agents) reported herein can be administered by any suitable means, including parenteral, intrapulmonary, and intranasal, as well as intralesional administration (if localized treatment is desired). Parenteral infusions include intramuscular, intravenous, intraarterial, intraperitoneal, or subcutaneous administration. Dosing can be by any suitable route, such as by injection (such as intravenous or subcutaneous injection), depending in part on whether administration is brief or chronic. Various dosing schedules are contemplated herein, including, but not limited to, single or multiple administrations over various time points, bolus administration, and pulse infusion.

[0184] The antibodies reported herein may be formulated, dosed, and administered in a manner consistent with good medical practice. Factors for consideration in this context include the particular disorder being treated, the particular mammal being treated, the clinical condition of the individual patient, the cause of the disorder, the site of delivery of the agent, the method of administration, the schedule of administration, and other factors known to medical practitioners. The antibodies need not be formulated with one or more agents currently used to prevent or treat the disorder in question, but are optionally formulated. The effective amount of such other agents will depend on the amount of antibody present in the formulation, the type of disorder or treatment, and other factors discussed above. These will generally be used in the same dosages and by the routes of administration as described herein, or at about 1-99% of the dosages described herein, or at any dosage and by any route empirically / clinically determined to be appropriate.

[0185] Lipid-based methods of transporting fusion constructs or compounds across the BBB include, but are not limited to, encapsulating the fusion constructs or compounds conjugated to monovalent binding entities that bind to receptors on the vascular endothelium of the BBB into liposomes, and coating monovalent binding entities (see, e.g., US 2002 / 0025313) into low density lipoprotein particles (see, e.g., US 2004 / 0204354) or apolipoprotein E (see, e.g., US 2004 / 0131692).

[0186] The appropriate dosage of the antibodies reported herein for the prevention or treatment of disease (when used alone or in combination with one or more other additional therapeutic agents) may depend on the type of disease being treated, the type of antibody, the severity and course of the disease (whether the antibody is administered for prophylactic or therapeutic purposes), previous treatments, the patient's clinical history and response to the antibody, and the judgment of the attending physician. The antibody is suitably administered to the patient at one time or over a series of treatments. Depending on the type and severity of the disease, about 1 μg / kg to 15 mg / kg (e.g., 0.5 mg / kg to 10 mg / kg) of the antibody may be an initial candidate dosage for administration to the patient, whether by one or more separate administrations or by continuous infusion, for example. A typical daily dosage may range from about 1 μg / kg to 100 mg / kg or more, depending on the factors mentioned above. For repeated administration over several days or longer, depending on the condition, treatment may generally be sustained until a desired suppression of disease symptoms occurs. One exemplary dosage of the antibody may range from about 0.05 mg / kg to about 10 mg / kg. Thus, one or more doses of about 0.5 mg / kg, 2.0 mg / kg, 4.0 mg / kg, or 10 mg / kg (or any combination thereof) may be administered to the patient. Such doses may be administered intermittently, for example, every week or every three weeks (e.g., such that the patient receives from about 2 to about 20, or, for example, 6 doses of the antibody). An initial higher loading dose, followed by one or more lower doses, may be administered. However, other dosage regimens may be useful. The progress of this therapy is easily monitored by conventional techniques and assays.

[0187] It is understood that any of the above formulations or methods of treatment may be carried out using the immunoconjugates reported herein instead of, or in addition to, the bispecific anti-human A-beta / human transferrin receptor antibodies.

[0188] III. Manufactured products In another embodiment reported herein, an article of manufacture is provided that includes materials useful for the treatment, prevention, and / or diagnosis of the disorders described above. The article of manufacture includes a container and a label or package insert on or associated with the container. Suitable containers include, for example, bottles, vials, syringes, IV solution bags, and the like. The container can be formed from a variety of materials, such as glass or plastic. The container holds the composition, either by itself or in combination with another composition effective for treating, preventing, and / or diagnosing a condition, and can have a sterile access port (e.g., the container can be an intravenous solution bag or a vial with a stopper pierceable by a hypodermic needle). At least one active agent in the composition is an antibody reported herein. The label or package insert indicates that the composition is used to treat the selected condition. Additionally, the article of manufacture can include (a) a first container containing a composition therein (the composition includes an antibody of the invention); and (b) a second container containing a composition therein (the composition includes an additional cytotoxic or otherwise therapeutic agent). The article of manufacture in this embodiment may further include a package insert indicating that the composition can be used to treat a particular condition. Alternatively, or in addition, the article of manufacture may further include a second (or third) container containing a pharma- ceutically acceptable buffer, such as bacteriostatic water for injection (BWFI), phosphate-buffered saline, Ringer's solution, and dextrose solution. It may further include other materials desirable from a commercial and user standpoint, including other buffers, diluents, filters, needles, and syringes.

[0189] It will be understood that any of the above articles of manufacture may comprise an immunoconjugate of the invention in place of, or in addition to, the bispecific antibodies reported herein.

[0190] IV. Working Examples The following are examples of methods and compositions of the present invention. It is understood that various other embodiments may be practiced given the general description provided above.

[0191] Materials & General Methods General information regarding the nucleotide sequences of human immunoglobulin light and heavy chains is given in Kabat, EA, et al., Sequences of Proteins of Immunological Interest, 5th ed., Public Health Service, National Institutes of Health, Bethesda, MD (1991). Amino acids of antibody chains are numbered and referred to according to the numbering according to Kabat (Kabat, EA, et al., Sequences of Proteins of Immunological Interest, 5th ed., Public Health Service, National Institutes of Health, Bethesda, MD (1991)).

[0192] Recombinant DNA Technology Standard methods were used to manipulate DNA as described in Sambrook, J., et al., Molecular cloning: A laboratory manual; Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York, 1989. Molecular biology reagents were used according to the manufacturers' instructions.

[0193] Gene synthesis The desired gene segments were prepared from oligonucleotides made by chemical synthesis. Long gene segments flanked by unique restriction endonuclease cleavage sites were assembled by annealing and ligation of oligonucleotides, including PCR amplification, and then cloned via the indicated restriction sites. The DNA sequences of the subcloned gene fragments were confirmed by DNA sequencing. Gene synthesis fragments were ordered according to the given specifications at Geneart (Regensburg, Germany).

[0194] DNA sequencing DNA sequences were determined by double-stranded sequencing performed at MediGenomix GmbH (Martinus, Germany) or Sequiserve GmbH (Vaterstetten, Germany).

[0195] DNA and protein sequence analysis and sequence data management GCG's (Genetics Computer Group, Madison, Wis.) software package version 10.2 and Infomax's Vector NT1 Advance suite version 8.0 were used for sequence generation, mapping, analysis, annotation, and illustration.

[0196] Expression vector For expression of the described bispecific antibodies, expression plasmids for transient expression (e.g. in HEK293-F) were applied, either based on a cDNA organization with or without the CMV-intron A promoter or on a genomic organization with the CMV promoter.

[0197] In addition to the antibody expression cassette, the vector contains: - an origin of replication allowing replication of this plasmid in E. coli, and - The β-lactamase gene that confers ampicillin resistance in E. coli.

[0198] The transcription unit for the antibody genes was composed of the following elements: - a unique restriction site at the 5' end, - the immediate early enhancer and promoter from the human cytomegalovirus, - intron A sequence in the case of cDNA organization, - a 5' untranslated region derived from a human antibody gene, - immunoglobulin heavy chain signal sequence, - each antibody chain encoding nucleic acid as cDNA or with genomic exon-intron organization, - a 3' untranslated region with a polyadenylation signal sequence, and - a unique restriction site at the 3' end.

[0199] Fusion genes encoding antibody chains were generated by PCR and / or gene synthesis and assembled by known recombination methods and joining of matched nucleic acid segments (e.g., using unique restriction sites in each vector). Subcloned nucleic acid sequences were verified by DNA sequencing. For transient transfection, larger amounts of plasmid were prepared by plasmid preparation from transformed E. coli cultures (Nucleobond AX, Macherey-Nagel).

[0200] For all constructs, the knob-into-hole heterodimerization technique was used with a typical knob (T366W) substitution in the first CH3 domain and the corresponding hole substitutions (T366S, L368A, and Y407V) in the second CH3 domain (as well as two additional introduced cysteine ​​residues S354C / Y349′C) (contained in the respective corresponding heavy chain (HC) sequences listed above).

[0201] Cell culture technology Standard cell culture techniques as described in Current Protocols in Cell Biology (2000), Bonifacino, JS, Dasso, M., Harford, JB, Lippincott-Schwartz, J. and Yamada, KM (eds.), John Wiley & Sons, Inc. are used.

[0202] Transient transfection in the HEK293-F system Bispecific antibodies are produced by transient expression. Therefore, transfection with the respective plasmids is performed using the HEK293-F system (Invitrogen) according to the manufacturer's instructions. Briefly, HEK293-F cells (Invitrogen) growing in suspension in serum-free FreeStyle™ 293 Expression Medium (Invitrogen) either in shake flasks or stirred fermenters were transfected with a mixture of the respective expression plasmids and 293fectin™ or Fectin (Invitrogen). For 2L shake flasks (Corning), HEK293-F cells were transfected at 1*10 in 600 ml. 6 The cells were seeded at a density of 10 cells / mL and incubated at 120 rpm and 8% CO. The next day, the cells were cultured at approximately 1.5*10 ng / mL using a mixture of A) 20 mL of Opti-MEM medium (Invitrogen) containing 600 μg of total plasmid DNA (1 μg / mL) and B) 20 mL of Opti-MEM medium supplemented with 1.2 mL of 293fectin or Fectin (2 μL / mL). 6 Cells were transfected at a cell density of 1000 cells / mL. Glucose solution was added during the course of fermentation according to glucose consumption. Supernatants containing secreted antibodies were harvested after 5-10 days and antibodies were either purified directly from the supernatants or the supernatants were frozen and stored.

[0203] Protein determination Protein concentrations of purified antibodies and derivatives were determined by determining the optical density (OD) at 280 nm using the molar extinction coefficient calculated based on the amino acid sequence according to Pace, et al., Protein Science 4 (1995) 2411-1423.

[0204] Determination of antibody concentration in the supernatant The concentration of antibodies and derivatives in cell culture supernatants was assessed by immunoprecipitation with protein A agarose-beads (Roche Diagnostics GmbH, Mannheim, Germany). Therefore, 60 μL of protein A agarose beads were washed three times in TBS-NP40 (50 mM Tris buffer, pH 7.5, supplemented with 150 mM NaCl and 1% Nonidet-P40). Then, 1–15 mL of cell culture supernatant was applied to the protein A agarose beads pre-equilibrated in TBS-NP40. After 1 h of incubation at room temperature, the beads were washed briefly on an Ultrafree-MC filter column (Amicon) once with 0.5 mL TBS-NP40, twice with 0.5 mL 2× phosphate-buffered saline (2×PBS, Roche Diagnostics GmbH, Mannheim, Germany) and four times with 0.5 mL 100 mM Na-citrate buffer (pH 5.0). Bound antibodies were eluted by adding 35 μl NuPAGE® LDS sample buffer (Invitrogen). Half of the sample was combined with NuPAGE® sample reducing agent or left unreduced, respectively, and heated at 70° C. for 10 min. Consequently, 5-30 μl was applied to 4-12% NuPAGE® Bis-Tris SDS-PAGE gels (Invitrogen) (using MOPS buffer for non-reduced SDS-PAGE and MES buffer with NuPAGE® antioxidant running buffer additive (Invitrogen) for reduced SDS-PAGE) and stained with Coomassie blue.

[0205] The concentration of antibodies in cell culture supernatants was quantitatively measured by affinity HPLC chromatography. Briefly, cell culture supernatants containing antibodies that bind to Protein A were applied to an Applied Biosystems Poros A / 20 column in 200 mM KH2PO4, 100 mM sodium citrate, pH 7.4, and eluted with 200 mM NaCl, 100 mM citric acid, pH 2.5 on an Agilent HPLC 1100 system. The eluted antibodies were quantified by UV absorbance and peak area integration. A purified standard IgG1 antibody served as a standard.

[0206] Alternatively, the concentration of antibodies and derivatives in cell culture supernatants was measured by Sandwich-IgG-ELISA. Briefly, StreptaWell High Bind Streptavidin A-96-well microtiter plates (Roche Diagnostics GmbH, Mannheim, Germany) were incubated with 100 μL / well of biotinylated anti-human IgG capture molecule F(ab')2 at 0.1 μg / mL for 1 h at room temperature or overnight at 4 °C.<h-Fcγ> The wells were incubated with BI (Dianova) and then washed three times with 200 μL / well of PBS, 0.05% Tween (PBST, Sigma). Then, 100 μL / well of a dilution series of each antibody-containing cell culture supernatant in PBS (Sigma) was added to the wells and incubated for 1-2 hours at room temperature on a shaker. The wells were washed three times with 200 μL / well of PBST and the bound antibodies were deconvoluted with 100 μl of F(ab')2 at 0.1 μg / mL as detection antibody.<hFcγ> Detection was by incubation with POD (Dianova) for 1-2 hours at room temperature on a shaker. Unbound detection antibody was removed by washing three times with 200 μL / well PBST. Bound detection antibody was detected by addition of 100 μL ABTS / well followed by incubation. Absorbance measurements were performed on a Tecan Fluor Spectrometer at a measurement wavelength of 405 nm (reference wavelength 492 nm).

[0207] Purification of preparative antibodies Antibodies were purified from filtered cell culture supernatants according to standard protocols. Briefly, antibodies were applied to a Protein A Sepharose column (GE healthcare) and washed with PBS. Elution of antibodies was achieved at pH 2.8, followed immediately by neutralization. Aggregated proteins were separated from monomeric antibodies by size-exclusion chromatography (Superdex 200, GE Healthcare) in PBS or in 20 mM histidine buffer (pH 6.0) containing 150 mM NaCl. Monomeric antibody fractions were pooled, concentrated (if required) using, for example, MILLIPORE Amicon Ultra (30 MWCO) centrifugal concentrators, and stored frozen at -20°C or 80°C. Part of the sample was submitted for subsequent protein analysis and analytical characterization (by SDS-PAGE, size-exclusion chromatography (SEC), or mass spectrometry).

[0208] SDS-PAGE The NuPAGE® Pre-Cast Gel System (Invitrogen Corp., USA) was used according to the manufacturer's instructions, specifically, 10% or 4-12% NuPAGE® Novex® Bis-TRIS Pre-Cast gels (pH 6.4) and NuPAGE® MES (reducing gels, with NuPAGE® antioxidant running buffer additive) or MOPS running buffer (non-reducing gels) were used.

[0209] CE-SDS Purity and antibody integrity were analyzed by CE-SDS using microfluidic Labchip technology (PerkinElmer, USA). Thus, 5 μL of antibody solution was prepared for CE-SDS analysis using the HT Protein Express Reagent Kit according to the manufacturer's instructions and analyzed on a LabChip GXII system using the HT Protein Express Chip. Data was analyzed using the LabChip GX Software.

[0210] Analytical Size Exclusion Chromatography Size exclusion chromatography (SEC) for the determination of antibody aggregation and oligomeric state was performed by HPLC chromatography. Briefly, Protein A purified antibodies were applied to a Tosoh TSKgel G3000SW column in 300 mM NaCl, 50 mM KH2PO4 / K2HPO4 buffer (pH 7.5) on a Dionex Ultimate® system (Thermo Fischer Scientific) or a Superdex 200 column in 2×PBS on a Dionex HPLC system (GE Healthcare). Eluted antibodies were quantified by UV absorbance and peak area integration. BioRad Gel Filtration Standard 151-1901 served as the standard.

[0211] mass spectrometry In this section we describe the characterization of the bispecific antibody with emphasis on its precise assembly. The predicted primary structure was analyzed by electrospray ionization mass spectrometry (ESI-MS) of the deglycosylated intact antibody and in the special case of the deglycosylated / limited LysC digested antibody.

[0212] Antibodies were deglycosylated with N-glycosidase F in phosphate or Tris buffer at 37° C. for up to 17 h at a protein concentration of 1 mg / ml. Limited LysC (Roche Diagnostics GmbH, Mannheim, Germany) digestion was performed with 100 μg of deglycosylated antibody in Tris buffer (pH 8) for 120 h at room temperature or 40 min at 37° C., respectively. Prior to mass spectrometry, samples were desalted via HPLC on a Sephadex G25 column (GE Healthcare). Total mass was determined via ESI-MS on a maXis 4G UHR-QTOF MS system (Bruker Daltonik) equipped with a TriVersa NanoMate source (Advion).

[0213] Chemical Decomposition Test Samples were divided into three aliquots and rebuffered in 20 mM His / His* HCl, 140 mM NaCl, pH 6.0, or in PBS and stored at 40° C. (His / NaCl) or 37° C. (PBS). Control samples were stored at −80° C.

[0214] After the incubation period was completed, samples were analyzed for relative activity concentration (BIAcore), aggregation (SEC), and fragmentation (capillary electrophoresis or SDS-PAGE) and compared to untreated controls.

[0215] thermal stability Samples were prepared at a concentration of 1 mg / mL in 20 mM histidine / histidine chloride, 140 mM NaCl, pH 6.0, transferred into an optical 384-well plate by centrifugation through a 0.4 μm filter plate and overlaid with paraffin oil. Hydrodynamic radii were repeatedly measured by dynamic light scattering on a DynaPro Plate Reader (Wyatt) while samples were heated from 25° C. to 80° C. at a rate of 0.05° C. / min.

[0216] Alternatively, samples were transferred into 10 μL microcuvette arrays and static light scattering data as well as fluorescence data upon excitation with a 266 nm laser were recorded with an Optim1000 instrument (Avacta Inc.) while they were heated from 25°C to 90°C at a rate of 0.1°C / min.

[0217] The onset temperature of aggregation is defined as the temperature at which the hydrodynamic radius (DLS) or scattered light intensity (Optim1000) begins to increase.

[0218] Alternatively, samples were transferred to a 9 μL multicuvette array. The multicuvette array was heated from 35° C. to 90° C. at a constant rate of 0.1° C. / min in an Optimue 1000 instrument (Avacta Analytical Inc.). The instrument continuously records the scattered light intensity of a 266 nm laser with data points approximately every 0.5° C. The light scattering intensity was plotted against temperature. The aggregation onset temperature (T_agg) is defined as the temperature at which the scattered light intensity begins to increase.

[0219] The melting temperature is defined as the inflection point in the fluorescence intensity versus wavelength graph.

[0220] Example 1 Expression and purification Bispecific antibodies were produced as described above in the general materials and methods section.

[0221] The bispecific antibodies were purified from the supernatant by a combination of Protein A affinity and size exclusion chromatography. The resulting products were characterized for identity by mass spectrometry and analytical properties such as purity by CE-SDS, monomer content, and stability.

[0222] The predicted primary structure was analyzed by electrospray ionization mass spectrometry (ESI-MS) of deglycosylated intact antibody and deglycosylated / plasmin digested or, alternatively, deglycosylated / limited LysC digested antibody as described in the General Methods section.

[0223] Additional analytical methods (eg, thermostability, mass spectrometry, and functional assessment) were applied only after Protein A and SEC purification.

[0224] Example 2 Determination of binding to Aβ1-40 fibrils in vitro by ELISA Bispecific antibody binding to fibrillar Aβ is measured by ELISA assay. Briefly, Aβ(1-40) is coated on Maxisorb plates at 7 μg / mL in PBS for 3 days at 37° C. to produce fibrillar Aβ, then dried for 3 hours at room temperature. Plates are blocked with 1% Crotein C and 0.1% RSA in PBS (blocking buffer) for 1 hour at room temperature, then washed once with washing buffer. Bispecific antibodies or controls are added at concentrations up to 100 nM in blocking buffer and incubated overnight at 4° C. After 4 washing steps, constructs are detected by adding anti-human IgG-HRP (Jackson Immunoresearch) diluted 1:10,000 in blocking buffer (1RT), followed by 6 washes and incubation in TMB (Sigma). After stopping color development with 1N HCl, absorbance is read at 450 nm.

[0225] Example 3 Determining binding to the transferrin receptor in vitro The binding of the bispecific antibodies to the mouse transferrin receptor is tested by FACS analysis on mouse X63.AG8-563 myeloma cells. If the Aβ antibodies show a certain tendency to bind nonspecifically to Ag8 cells, specific binding can be quantified by co-incubation with a 20-fold excess of anti-mouse TfR antibody. Cells are harvested by centrifugation, washed once with PBS and diluted with 5 × 10 4 Individual cells are incubated with a 1.5 pM to 10 nM dilution series of the polypeptide fusion with or without 200 nM anti-mouse TfR antibody in 100 μL of RPMI / 10% FCS for 1.5 h on ice. After washing twice with RPMI / 10% FCS, cells are incubated with goat anti-human IgG conjugated to phycoerythrin (Jackson Immunoresearch) at a dilution of 1:600 ​​in RPMI / 19% FCS for 1.5 h on ice. Cells are washed again, resuspended in RPMI / 10% FCS, and phycoerythrin fluorescence is measured on a FACS-Array instrument (Becton-Dickinson).

[0226] Example 4 Surface plasmon resonance-based binding assay for human TfR-antibody interactions Binding experiments were performed on a BIAcore B 4000 (GE Healthcare) equipped with a C1 sensor chip (GE Healthcare, cat.no. BR1005-35) pretreated with anti-human Fab antibody (GE Healthcare, cat.no 28-9583-25) using standard amine coupling chemistry procedures according to the vendor's manual.

[0227] For kinetic measurements, sample antibodies were immobilized at 25° C. in phosphate buffered saline (pH 7.4), 0.05% Tween 20, applying a contact time of 60 s and a flow rate of 10 μL / min. Recombinant His6-tagged human transferrin receptor (R&D systems, cat.no 2474-TR-050) was applied in increasing concentrations and the signal was monitored over time. An average time interval of 150 s for association time and 600 s for dissociation time at a flow rate of 30 μL / min was recorded. Data were fitted using a 1:1 binding model (Langmuir isotherm).

[0228] Example 5 Staining of native human β-amyloid plaques from brain sections of Alzheimer's disease patients by indirect immunofluorescence using the bispecific antibody reported herein Bispecific antibodies can be tested for their ability to stain native human β-amyloid plaques by immunohistochemical analysis using indirect immunofluorescence. Specific and sensitive staining of true human β-amyloid plaques can be demonstrated. Cryostat sections of unfixed tissue from temporal cortex obtained postmortem from patients diagnosed positive for Alzheimer's disease are labeled by indirect immunofluorescence. A two-step incubation is used to detect bound bispecific antibodies, revealed by affinity-purified goat anti-human (GAH555) IgG(H+L) conjugated to Alexa 555 dye (Molecular Probes). Controls include an irrelevant human IgG1 antibody (Sigma) and secondary antibodies alone, which should all give negative results.

[0229] Example 6 In vivo β-amyloid plaque activation by the bispecific antibody reported herein in a mouse model of Alzheimer's disease Bispecific antibodies can be tested for their ability to immunoactivate β-amyloid plaques in vivo in APP / PS2 double transgenic mice (Richards, J. Neuroscience, 23 (2003) 8989-9003), a mouse model of AD-related amyloidosis. This allows for the assessment of the degree of brain penetration and binding to amyloid β plaques. The fusion polypeptides can be administered at different doses compared to naked anti-Aβ monoclonal antibodies, and after 6 days the animals are perfused with phosphate buffered saline and the brains are frozen on dry ice and prepared for cryosectioning.

[0230] The presence of antibody bound to β-amyloid plaques can be assessed using unfixed frozen sections by single-label indirect immunofluorescence with goat anti-human IgG (H + L) (Molecular Probes) conjugated to Alexa555 dye (GAH555) at a concentration of 15 μg / mL for 1 hour at room temperature. Counterstaining for amyloid plaques can be performed by incubation with mouse monoclonal antibody BAP-2 against Aβ conjugated to Alexa 488 at a concentration of 0.5 μg / mL for 1 hour at room temperature. Slides are embedded in fluorescent mounting medium (S3023 Dako) and imaging is performed by confocal laser microscopy.

[0231] The foregoing invention has been described in detail by way of illustration and examples, for purposes of clarity of understanding, but the descriptions and examples should not be construed as limiting the scope of the invention. The disclosures of all patent and scientific literature cited herein are expressly incorporated by reference in their entireties.

Claims

1. a) an antibody comprising two pairs of antibody light chains and antibody heavy chains, the binding site formed by each of the heavy and light chain pairs specifically binding to a first antigen; and b) one additional Fab fragment fused to the C-terminus of one of the heavy chains of the above antibody, the binding site of which specifically binds to a second antigen, each of the antibody light chains comprises in the constant light domain (CL) the amino acid residue arginine at position 123 (instead of the wild-type glutamic acid residue; E123R mutation) and the amino acid residue lysine at position 124 (instead of the wild-type glutamine residue; Q124K mutation) (numbering according to Kabat); each of the antibody heavy chains comprises in the first constant heavy chain domain (CH1) a glutamic acid residue at position 147 (instead of the wild-type lysine residue; K147E mutation) and a glutamic acid residue at position 213 (instead of the wild-type lysine amino acid residue; K213E mutation) (numbering according to the Kabat EU index); An additional Fab fragment that specifically binds to a second antigen comprises a domain crossover such that the constant light domain (CL) and the constant heavy domain 1 (CH1) are replaced by each other; and A bispecific antibody, wherein the first antigen is human A-beta protein and the second antigen is the human transferrin receptor.

2. The antibody of claim 1, wherein an additional Fab fragment is fused to the C-terminus of the heavy chain by a peptide linker.

3. a) the heavy chain fused to the additional Fab fragment has as its C-terminal heavy chain amino acid residue the tripeptide LSP, the proline of which is fused via a peptide bond directly to the first amino acid residue of the additional Fab fragment or of a peptide linker; and 3. The antibody of claim 1 or 2, wherein the heavy chain that is not fused to an additional Fab fragment has the tripeptide LSP, or SPG, or PGK as the C-terminal heavy chain amino acid residue.

4. a) a full-length human antibody of subclass IgG1; b) a full-length antibody of human subclass IgG4; c) a full-length antibody of human subclass IgG1 with the mutations L234A, L235A, and P329G; d) a full-length antibody of human subclass IgG4 with the mutations S228P, L235E, and P329G; e) A full-length antibody of human subclass IgG1 with the mutations L234A, L235A, and P329G in both heavy chains, and the mutations T366W and S354C in one heavy chain, and the mutations T366S, L368A, Y407V, and Y349C in the respective other heavy chain. f) a full-length antibody of human subclass IgG4 with the mutations S228P and P329G in both heavy chains, and the mutations T366W and S354C in one heavy chain, and the mutations T366S, L368A, Y407V, and Y349C in each of the other heavy chains; g) a full-length antibody of human subclass IgG1 with the mutations L234A, L235A, P329G, I253A, H310A, and H435A in both heavy chains, and the mutations T366W and S354C in one heavy chain, and the mutations T366S, L368A, Y407V, and Y349C in the respective other heavy chain; h) a full-length antibody of human subclass IgG1 with the mutations L234A, L235A, P329G, M252Y, S254T, and T256E in both heavy chains, and the mutations T366W and S354C in one heavy chain, and the mutations T366S, L368A, Y407V, and Y349C in the respective other heavy chain, or i) a full-length antibody of human subclass IgG1 with the mutations L234A, L235A, P329G, H310A, H433A, and Y436A in both heavy chains, and the mutations i) T366W, and ii) S354C or Y349C in one heavy chain, and the mutations i) T366S, L368A, and Y407V, and ii) Y349C or S354C in the respective other heavy chain. The antibody according to any one of claims 1 to 3,

5. The bispecific antibody i) a light chain having 70% or greater sequence identity to SEQ ID NO: 01; ii) a heavy chain having 70% or greater sequence identity to SEQ ID NO:02; iii) a light chain having 70% or greater sequence identity to SEQ ID NO:03; and iv) The antibody of any one of claims 1 to 4, comprising a heavy chain Fab fragment having 70% or more sequence identity to SEQ ID NO:

04.

6. The antibody of any one of claims 1 to 4, wherein the bispecific antibody comprises a light chain having the amino acid sequence of SEQ ID NO: 01, a heavy chain having the amino acid sequence of SEQ ID NO: 02, a light chain having the amino acid sequence of SEQ ID NO: 03, and an antibody Fab fragment comprising the amino acid sequence of SEQ ID NO:

04.

7. The antibody of any one of claims 1 to 6, wherein the antibody is monoclonal.

8. The antibody of any one of claims 1 to 7, wherein the human A-beta binding site comprises the VH sequence in SEQ ID NO: 18 (including post-translational modifications of that sequence) and the VL sequence in SEQ ID NO: 19 (including post-translational modifications of that sequence).

9. The antibody of any one of claims 1 to 8, wherein the human transferrin receptor binding site comprises the VH sequence in SEQ ID NO: 20 (including post-translational modifications of that sequence) and the VL sequence in SEQ ID NO: 21 (including post-translational modifications of that sequence).

10. A pharmaceutical formulation comprising the antibody of any one of claims 1 to 9 and a pharma- ceutically acceptable carrier.

11. The antibody according to any one of claims 1 to 9 for use as a medicament.

12. The antibody according to any one of claims 1 to 9 for the treatment of Alzheimer's disease.

13. Use of an antibody according to any one of claims 1 to 9 in the manufacture of a medicament.

14. 14. The use according to claim 13, wherein the medicament is for the treatment of Alzheimer's disease.

15. 14. The use according to claim 13, wherein the medicament is for inhibiting / slowing down the formation of plaques in the brain.

16. A method of treating an individual with Alzheimer's disease, comprising administering to the individual an effective amount of an antibody according to any one of claims 1 to 9.

17. A method of inhibiting / slowing down the formation of plaques in the brain of an individual comprising administering to the individual an effective amount of an antibody described in any one of claims 1 to 9 to inhibit / slow down the formation of plaques in the brain.

Citation Information

Patent Citations

  • Blood-brain barrier shuttle

    JP2015528452A

  • Bispecific anti-human A-beta / human transferrin receptor antibodies and methods of use thereof

    JP7530935B2

  • Monovalent blood brain barrier shuttle modules

    WO2015101588A1